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PROFORMA 
1. NAME: 
2. AGE: 
3. IPNO: 
4. RESIDENCE: 
5. URBAN/RURAL: 
6. BMI: 
7. NUTRITIONAL STATUS: 
8. OBSTETRIC FORMULA :   
 
i. Gravida 
ii. Parity 
iii. No. Of living Children 
iv. Abortions. 
9. WHERE BOOKING AND IMMUNISATION DONE: 
10. DATE AND TIME OF FIRST VISIT: 
11. MATERNAL ALPHA FETOPROTEIN:  
12. ULTRASOUND FINDINGS IN SECOND TRIMESTER 
13. ULTRASOUND FINDINGS IN THIRD TRIMESTER 
 
 
14. PERIOD OF ADMISSION 
 
 AN after 24 weeks 
 AN after 28 weeks 
 Intrapartum. 
 Postpartum/Postnatal upto 24hrs 
15. REASONS FOR ADMISSION 
  A).Safe confinement 
  B).APH  
  C).PPH 
  D).Shock 
  E).Bowel obstruction 
  F).Wound dehiscence 
  G).Infection 
  H).Abcess 
  I).Bladder problems 
  J).Others 
16. CONDITION ON ADMISSION : 
 Stable/Semiconsious /Unconscious 
17. WAS SHE REFERRED FROM ANOTHER CENTRE? 
 Yes/No/Don’t know 
 If yes type facility from which referred. 
 PHC 
 24*7 PHS 
 RURAL HOSPITAL 
 DISTRICT HOSPITAL 
 Private Hospital 
 Private Clinic 
 SDH/CHC 
 Others 
18. ANTECEDENT RISK FACTORS: 
 ANEMIA 
 PIH 
 PREV.LSCS 
 D.M 
 CHRONIC ILLNESS 
 BLEEDING DISORDER 
 JAUNDICE 
 MALNOURISHED 
RISK FACTORS:1). Prior Caesarean Delivery, 2). Multipartly, 3). 
Complete Previa 
19. HISTORY OF BLEEDING /DRANING PV: 
20. DATE,TIME OF DELIVERY 
21. MODE OF DELIVERY: LSCS/SVD/INSTRUMENTAL 
22. PLACE OF DELIVERY 
23. PERSON WHO CONDUCTED THE DELIVERY 
24. H/O INSTRUMENTAL DELIVERY. 
25 WAS IT PROLONGED LABOUR 
26. H/O MANUAL REMOVAL OF PLACENTA 
27. BABY DETAILS: 
   A).WEIGHT 
   B).APGAR 
   C).NEONATAL ADMISSION 
28. LSCS  
  a. ELECTIVE 
  b. EMERGENCY 
29. INDICATION FOR LSCS 
30. COMPLICATION DURING LSCS/VAGINAL DELIVERY 
 DENSE ADHESIONS 
 ANTERIOR AND LOW LYING PLACENTA 
 POSTERIOR AND LOW LYING 
 CENTRAL PLACENTA PREVIA 
 ATONIC PPH 
 PLACENTA ACCRETA INCRETA PERCRETA 
URINARY BLADDER INVOLVEMENT 
BOWEL INVOLVEMENT-PROCEEDED TO SUB – TOTAL 
HYSTERECTOMY 
 PROCEEDED TO TOTAL HYSTERECTOMY 
31. CONSERVATIVE MANAGEMENT  /NASG APPLIED: 
32. POST PARTUM 
  A).FEVER 
  B).FOUL SMELLING VAGINAL DISCHARGE 
  C).CHRONIC COUGH/CONSTIPATION 
  D).EXCESSIVE BLEEDING 
  E).ABDOMINAL DISTENSION 
33. NUMBER OF BLOOD TRANSFUSION: 
34. COMPLICATION IF ANY: 
35. PERIOD OF HOSPITAL STAY: 
36. POST OPERATIVE OUTCOME: 
37. MATERNAL MORTALITY/  NEAR MISS MORTALITY: 
  
MASTER CHART  
S.NO IP NO AGE PARITY MSAFP MOM PREV.LSCS PREV.ABOR PREV.V.D
MATERNAL 
OUTCOME 
LSCS 
GA 
CESA. 
HYS 
HPE 
FINDINGS 
1 3041 22 1 85 0.8 0 0 0 1 38 0 0 
2 3243 24 2 89 0.8 0 1 1 2 36 0 0 
3 3377 21 2 121 1.1 1 0 0 2 34 0 0 
4 3585 25 2 262 2.5 0 0 1 1 39 0 0 
5 3461 26 2 209 2 2 1 0 2 37 0 0 
6 3624 24 2 241 2.3 1 1 0 2 36 0 0 
7 3554 25 2 26 0.2 1 0 0 2 37 0 0 
8 2943 35 2 226 2.2 2 0 0 2 35 1 2 
9 108078 22 2 119 1.1 0 1 2 1 36 0 0 
10 118486 30 2 279 2.7 0 0 1 1 40 0 0 
11 5395 23 1 215 2.3 0 0 0 2 39 0 0 
12 5660 22 1 136 1.7 0 0 0 2 34 0 0 
13 5656 28 1 106 1.1 0 0 0 2 36 0 0 
14 6778 33 2 63 0.6 0 0 1 2 37 0 0 
15 10559 29 2 92 1.01 0 0 1 1 34 0 0 
16 13959 34 2 181 1.7 1 0 0 2 33 0 0 
17 3124 30 2 271 2.9 1 1 0 2 34 1 2 
18 14225 32 2 183 1.8 1 3 0 2 35 1 2 
19 6310 26 2 150 1.4 0 0 2 2 32 0 0 
20 14102 32 2 201 1.9 0 1 0 2 27 1 4 
21 6731 34 2 198 1.9 2 0 0 2 36 1 3 
22 16361 24 2 189 1.87 1 0 0 2 36 0 0 
23 16603 34 2 177 1.9 0 0 1 2 37 1 2 
24 771 24 2 221 2.1 1 0 0 2 36 1 2 
25 15955 26 2 126 1.2 1 0 0 2 36 0 0 
26 16880 21 2 200 2.2 0 1 0 2 38 0 0 
27 1702 20 2 246 2.4 0 1 0 1 35 0 0 
28 17421 28 2 185 1.8 0 1 0 1 37 0 0 
29 17378 27 2 142 1.3 0 1 2 1 39 0 0 
30 17503 26 1 76 0.7 0 0 0 2 38 0 0 
31 16957 27 1 107 1.05 0 0 0 2 37 0 0 
32 18046 25 2 204 2.01 1 0 0 2 34 0 0 
33 19597 28 1 107 1.05 0 0 0 1 37 0 0 
34 19746 20 1 83 0.8 0 0 0 1 37 0 0 
35 19029 24 2 23 0.22 0 1 0 1 38 0 0 
36 20448 20 1 84 0.82 0 0 0 1 39 0 0 
37 20491 23 1 52 0.4 0 0 0 1 32 0 0 
38 20346 26 2 44 0.43 0 0 1 1 41 0 0 
39 20539 20 1 23 0.21 0 0 0 1 40 0 0 
40 20582 23 2 112 1.1 0 0 1 1 40 0 0 
41 19812 18 1 73 0.6 0 0 0 1 39 0 0 
42 1027 28 2 223 2.2 2 1 0 2 36 1 3 
43 20604 27 2 89 0.8 0 1 2 1 39 0 0 
44 2943 35 2 202 2 2 0 0 2 34 1 1 
45 19750 34 2 23 0.2 0 1 2 1 37 0 0 
46 20464 34 2 97 0.9 0 1 1 1 38 0 0 
47 20431 18 1 99 0.9 0 0 0 1 40 0 0 
48 20390 26 2 73 0.72 0 0 1 1 35 0 0 
49 20621 26 1 60 0.56 0 0 0 1 39 0 0 
50 20612 21 1 91 0.9 0 0 0 1 39 0 0 
51 20717 22 2 88 0.7 0 0 2 1 40 0 0 
52 3860 20 2 180 0.8 1 0 0 2 36 0 0 
53 4156 28 2 174 1.72 1 1 0 2 36 1 1 
54 19951 25 2 63 0.6 0 0 1 1 38 0 0 
55 20739 25 2 43 0.41 0 0 1 1 39 0 0 
56 20782 21 1 99 0.98 0 0 0 1 39 0 0 
57 20808 22 1 53 0.52 0 0 0 1 41 0 0 
58 4152 25 2 213 2.1 1 2 0 2 37 1 2 
59 20639 22 2 254 2.5 0 0 1 1 38 0 0 
60 20804 23 1 176 1.4 0 0 0 1 38 0 0 
61 6646 23 1 212 2.09 2 2 0 2 34 1 1 
62 7390 20 2 101 1 1 0 0 2 35 1 1 
63 17033 24 1 108 1.06 0 0 0 1 39 0 0 
64 17138 31 2 124 1.09 0 1 2 1 39 0 0 
65 16799 33 2 98 0.7 0 3 2 1 39 0 0 
66 17763 29 1 134 1.07 0 0 0 1 34 0 0 
67 17771 23 1 74 0.7 0 0 0 1 37 0 0 
68 8332 24 2 133 1.27 0 0 2 2 33 1 1 
69 17905 21 2 94 0.92 0 0 2 1 39 0 0 
70 18842 25 1 174 1.3 0 0 0 1 39 0 0 
71 18726 24 2 113 0.9 0 0 0 1 39 0 0 
72 19064 31 1 81 0.6 0 0 0 1 38 0 0 
73 9304 22 2 25 0.2 0 2 0 2 37 1 1 
74 14102 28 2 250 2.6 1 1 0 2 35 1 1 
75 18376 25 2 131 1.04 1 0 1 2 36 0 0 
76 19521 30 1 144 1.4 0 0 0 2 30 0 0 
77 18058 29 2 101 1.1 0 1 0 1 39 0 0 
78 17503 26 1 143 1.4 0 0 0 2 36 0 0 
79 18726 31 2 93 0.9 1 0 0 1 38 0 0 
80 17103 21 1 130 1.2 0 0 0 2 37 0 0 
81 19391 26 1 33 0.3 0 0 0 1 39 0 0 
82 16957 23 1 139 1.37 0 0 0 2 37 0 0 
83 21230 30 2 152 1.49 0 1 0 2 38 0 0 
84 19691 24 1 76 0.75 0 0 0 1 39 0 0 
85 18221 22 2 56 0.5 0 1 0 1 39 0 0 
86 20205 24 1 23 0.2 0 0 0 1 33 0 0 
87 20030 25 2 231 2.28 1 0 0 2 35 1 1 
88 20491 23 1 49 0.4 0 0 0 1 38 0 0 
89 20604 27 2 61 0.6 0 1 2 1 38 0 0 
90 19750 34 2 71 0.5 0 1 1 1 36 0 0 
91 20520 22 1 80 0.64 0 0 0 1 37 0 0 
92 20818 27 2 201 2 1 0 0 2 35 0 0 
93 20531 32 2 68 0.6 0 0 1 1 39 0 0 
94 21033 23 1 41 0.4 0 0 0 1 39 0 0 
95 21137 28 2 251 2.5 1 0 0 2 38 0 0 
96 21040 19 1 13 0.1 0 0 0 1 39 0 0 
97 21066 30 2 211 2 3 1 0 2 34 1 4 
98 20702 24 2 39 0.3 0 1 1 1 39 0 0 
99 20936 27 2 23 0.2 0 0 3 1 38 0 0 
100 21230 30 2 212 2.2 0 0 1 2 39 0 0 
 
 
INTRODUCTION 
    The term placenta previa is used to describe a placenta that is 
implanted over or very near the internal os. 
    With any degree of placenta previa in later weeks of gestation, a 
certain degree of spontaneous placental separation is inevitable, which 
leads to unpredicted antepartum hemorrhage. It is one of obstetrical 
emergencies posing a threat to the maternal and fetal life The incidence of 
placenta previa is found to be 5% during second trimester; however it is 
only 0.5% at the time of delivery due to differential growth of uterus. 
   Nowadays the incidence of placenta previa and placental invasion 
are increasing due to rapidly increasing deliveries by caesarean section. 
This study is done to know the association of maternal serum alpha 
fetoprotein taken at 16-20 weeks in sonographically diagnosed placenta 
previa patients for persistence of placenta previa and its invasiveness at 
term as well as predictor for the same in our institution. 
   Diagnosis of placenta previa and its invasiveness by tissue 
diagnosis is 100% accurate, however high resolution sonography and 
MRI can detect the placenta previa persistence and its invasion only in 
 
 
 
 
2 
 
later weeks of pregnancy.  Thus the estimation of maternal serum alpha 
fetoprotein in 16-20 weeks in these patients can predict the persistence 
and invasion of placenta previa at term. 
   Thus this test results will assist the clinician to counsel women in 
2nd trimester itself in regard of persistent placenta previa and its invasion 
and advise these high risk antenatal mothers to get prompt management 
in tertiary care centre like our institution and for earlier termination of 
pregnancy so that we can reduce the perinatal and maternal morbidity and 
mortality to certain extent in our developing country. 
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AIM OF THE STUDY 
1. To evaluate the relationship between maternal serum Alpha 
fetoprotein and the risk of persistent placenta previa 
2. To evaluate and know about correlation of different values of 
MSAFP and the degree of invasion of placenta previa. 
3. To decide on early termination of pregnancy and to save life of 
both mother and the baby. 
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MATERIALS AND METHODS 
STUDY:   
             A prospective analytical study 
PLACE: 
           Institute of Obstetrics and Gynaecology 
PERIOD: 
           April 2014 - September 2014 
SAMPLE SIZE: 
          100 cases 
INCLUSION CRITERIA: 
         Pregnant women with sonographic evidence of placenta previa at 
15-20 weeks of gestation 
EXCLUSION CRITERIA: 
Delivery before 24 weeks of gestation 
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Anomalous foetus 
Multiple pregnancy 
IUFD                                                                                                                             
Placental abnormalities   
STUDY MATERIAL: 
3 ml of venous blood was collected from antenatal mothers with 
sonographic evidence of placenta previa at 15-20 weeks of gestation who 
attended in ANOP at IOG. 
Estimation of MSAFP was done by chemiluminescence assay from 
the serum which was collected. Multiples of median (MOM) values had 
been derived for our population, adjusted for gestational age. 
PRIMARY OUTCOME: 
The pregnancies in which caesarean delivery was performed for 
persistent placenta previa is our primary outcome. 
 Additional outcomes are indicated caesarean hysterectomy and 
pathological evidence of placental invasion.    
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REVIEW OF LITERATURE 
GENERAL ASPECTS: 
   Third trimester bleeding is one of the most ominous complication 
in pregnancy and it complicates 3% of all pregnancies. Third trimester 
obstetric hemorrhage seems to be the third leading cause of both maternal 
and perinatal morbidity and mortality. The obstetric cause of bleeding in 
third trimester being hazardous has to be differentiated from  the non 
obstetric causes. 
CAUSES OF THIRD TRIMESTER BLEEDING: 
OBSTETRIC                                         NON OBSTETRIC                                 
1. Bloody show                                             1. Cervicitis 
2. Placenta previa                                          2. Cervical polyp 
3. Abruptio placenta                                      3. Cervical erosion 
4. Vasa previa                                                4. Vaginitis 
5. Disseminated intravascular coagulation  5. Genital tract disease 
6. Uterine rupture                                          6. Vulval, vaginal varicosities 
7. Marginal sinus bleeding                          7. Cervical cancer 
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DEVELOPMENT OF THE PLACENTA: 
        The placenta is a remarkable organ performing many diverse 
functions including transport of gases and metabolites, immunological 
protection and production of steroids and protein hormones. The zygote 
after repeated metabolic divisions gets converted into a blastocyst. The 
outer layer of the blastocyst is called trophoblast and the inner cell mass 
is called embryoblast. The trophoblast rapidly proliferates and 
differentiates into outer syncitiotrophoblast and an inner cytotrophoblast. 
The primary, secondary, tertiary villi are formed by the 
syncitiotrophoblast and the intervillous space is formed by 
cytotrophoblast. Until the end of 16th week the placenta grows in 
thickness and circumference due to the growth of the chorionic villi and 
expansion of the intervillous space. The implanted placenta by nature 
separates during the third stage of labour by a multiphasic process. 
 
PLACENTAL MIGRATION 
 The apparent peripatetic nature of the placenta has been well established 
by King 1973.1 Sanderson and Milton in 1991 reported that the placenta 
lies close to the internal os but not over it during the late second 2nd 
trimester or early 3rd trimester are unlikely to persist at term2. Chama 
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20043, Dashe  2002, Laughon 2005 shown that the persistence of placenta 
previa being diagnosed sonographically  before 28 weeks is greater in 
women who have had a prior caesarean delivery. 
PLACENTA PREVIA 
DEFINITION: 
When the placenta is implanted partially or completely over the lower 
uterine segment (over and or adjacent to the internal os) is called placenta 
previa.The term previa (in Latin, in front of) denotes the position of the 
placenta in relation to the presenting part. 
 
 
 
 
 
 
 
 
 
APH  complicates 2-5% of the pregnancies. Placenta previa and abruptio 
placenta remains the important causes of APH. 
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CLASSIFICATION: 
1.Digital assessment: 
Total placenta previa: The internal os is completely covered by placenta. 
Marginal placenta previa: The edge of the placenta is at the margin of the 
internal os.  
Partial placenta previa: The internal os is partially covered by internal os   
Low lying placenta: The placenta is implanted in the lower uterine 
segment but the placental edge does not reach the internal os but it is 
within 2 cm of internal cervical os. 
 Vasa previa: The fetal vessels come through membrane and present at 
the  cervical os. 
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With both partial and complete placenta previa, certain degree of 
spontaneous placental separation is an inevitable consequence of lower 
uterine segment formation and cervical dilatation but separation is usually 
associated with hemorrhage (APH). 
Grades of placenta previa: 
Grade 1:  The placenta is in the lower segment, but the lower edges 
does not reach the internal os. 
Grade 2: The lower edge of the low-lying placenta reaches, but does 
not cover, the internal os. 
Grade 3:  The placenta covers the internal os asymmetrically. 
Grade 4 :  The placenta covers the internal os symmetrically. 
Grade 1, 2 are minor degree of placenta previa. 
Grade 3, 4 are major degree of placenta previa. 
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2.Ultrasound classification: 
Total previa:  
When placenta completely covers the internal cervical os and extends 
over both lips of the cervix. 
Partial previa: 
When the placenta does not cover the internal os but its lower border is 
within 2 cms of the internal os 
Low lying placenta: 
When the placental border is more than 2 cms from the internal os 
Bhide et al., 2003 have shown that caesarean section rate is 90% when 
the placental edge - internal os distance less than 2 cm and 37% when it is 
more than 2 cms4. 
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HISTORICAL ASPECTS: 
Columbus first coined the term placenta which meant a circular cake in 
Latin. In 1775, Edward of Norwich made the first clinical presentation  
between abruptio placenta and placenta previa. 
EPIDEMIOLOGY: 
The prevalence of clinically evident Placenta previa at term is 
estimated to be approximately 5 per 10005. Placenta previa occurs in 0.3-
0.5% of  pregnancies. Placenta previa occurs in one of every 250 births. 
One third of all APH occurs due to placenta previa. Perinatal mortality 
rate of placenta previa is 3-4 times higher than normal pregnancies. 
The risk increases 1.5 to 5 fold with history of caesarean delivery. 
The frequency of complete placenta previa ranges from 20-45%, partial 
placenta previa accounts for approximately 30% and marginal placenta 
previa accounts for the remaining 25-50%.Martin and co-workers 2005 
reported that incidence of placenta previa s 1 in 300 deliveries6. 
Placenta previa occurs in 2.8 of 1000 singleton pregnancies and 3.9 
of 1000 twin pregnancies.The incidence of caesarean hysterectomies due 
to intractable postpartum hemorrhage is 5.3%with a 3-4 fold increase in 
perinatal mortality compared with normal pregnancies. 
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ETIOLOGY: 
The exact cause of the implantation of the placenta in the lower segment 
is not known. The following theories are postulated: 
1. Dropping down theory:   The fertilised ovum drops down and implants 
in the lower segment. Poor decidual reaction in the upper segment may be 
the cause. 
2. Failure of zona pellucida to disappear in time can be a hypothetical 
possibility that explains the formation of central placenta previa. 
3. Persistence of chorionic cavity in the decidua capsularis and its 
subsequent development into capsular placenta which comes in contact 
with decidua vera of the lower uterine segment can explain the formation 
of lower degrees of placenta previa. 
4.Defective deciduas results in spreading of chorionic villi over a wide 
area in the uterine wall to get nourishment. During this process, not only 
the placenta becomes membranous but encroaches into lower segment.  
5.Big surface area of the placenta as in twins may encroach into  lower 
uterine segment 
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RISK FACTORS: 
1.Advancing maternal age:  
Advancing maternal age increases the risk of placenta previa.In the 
FASTER7 trial, first and second trimester evaluation of risk, those older 
than 35 years had a 1.1% of placenta previa compared with that of 0.5% 
for women lesser than 35.  Frederickson and colleagues in 1999 reported 
that increasing maternal age increases the overall incidence of placenta 
previa, thus increasing maternal age  has increased the overall incidence 
of previa from 0.3% in 1976 to 0.7% in 19978. 
2. Multiparity: 
Multiparity is associated with an increased risk for placenta 
previa.Babinski and colleagues, 1999 reported that 2.2% increased 
incidenceof placenta previa in women with para 5 and above9. 
3.Multifetal Gestation: 
Ananth and associates 2003 reported that the rate of placenta previa to be 
40% higher in multifetal gestation compared with singleton10. 
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4.Prior caesarean delivery: 
Prior caesarean delivery increases the risk for placenta previa. 
Silver and associates 2006 noted that the risk of previa increases 
inwomen who had prior caesarean delivery11.Incidence is over 1.3% for 
one prior caesarean delivery and  3.4% who had 6 or more caesarean 
delivery. Miller and associates 1996 cited a 3 fold increase in previa in 
women with a prior caesarean delivery12. Gesteland and co-workers 2004 
and William and colleagues reported that likelihood of previa was 
increased more than 8 fold in female with  parity greater than 4 and more 
than 4 prior caesarean delivery13. 
5.Smoking: 
William and colleagues reported that the relative risk of placenta 
previa is increased 2 fold in female who smoked cigarettes14. These 
findings were confirmed by Ananth 2003, Handler 1994, Usta 2005.It 
was theorised that carbon dioxide, hypoxemia caused compensatory 
placental hypertrophy, defective decidual vascularisation. 
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6.Prior curettage: 
7.Abruptio placenta: In 10% of women with abruptio may have 
coexistent placenta previa17 (Konje and Taylor 2001) 
8.Endometritis: According to Faiz & Ananth, 2003 placenta previa 
occurs in patients with endometritis16 
9.Uterine scar. 
10.Recurrent placenta previa. 
PREDICTORS 
1. ULTRASONOGRAPHY 
2. BIOCHEMICAL MARKERS. 
ULTRASONOGRAPHY :  
TRANSVAGINAL SONOGRAPHY: 
RCOG and National institute for health and clinical excellence support 
placental localization in routine ultrasound scanning at around 20 weeks 
of gestation.TVS is safe and should be used to improve the accuracy of 
the diagnosis of low lying placenta at 20 weeks of gestation. Various 
studies like Taipale et al 1988, Becker et al 2001, Fung et al 2011  did  
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ultrasound at 18-23 weeks of gestation, concluded that significant 
migration of low lying placenta is unlikely if the placenta overlaps the 
internal os by 25mm at 20-23 weeks of gestation15. 
 
    
 
 
 
 
 
In asymptomatic patients follow up scan is a must until 36 weeks, but in 
case of placenta accreta do scan in 32 weeks for early decision. Women 
with both anterior or central placenta previa and two or more previous 
caesarean delivery have a 40% risk of placenta accreta. The presence of 
vascularisation of lacunae had the highest sensitivity of 79% with positive 
predictive value of 93%. 
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   The persistence of placenta previa at term is best predicted by 
ultrasound when the placenta overlaps the internal os by 1.4 cm at 10 
to16 weeks or 2 cm at 20 to23 weeks of gestation. Mustafa et al. reported 
that if placenta overlaps by 2.3 cm at 11 to 14 weeks the probability of 
persistent placenta previa at term is 8% with sensitivity of  83% and 
specificity of 86%. 
    Ghourah et al., reported that if the leading edge of the placenta  is 
less than 1 cm thickness and or the angle of placental edge is less than 45 
degree is called thin low lying placenta and any other type of placenta 
more than this measures is thick low lying placenta. The presence of thick 
low lying placenta can predict the delivery complications18. 
   Cervical length as an outcome predictor in placenta previa was 
reported by M. Busquest and co workers. As mean cervical length less 
than 29 mms before 34 weeks in placenta previa patients is associated 
with caesarean section complications. 
Hasegawa and associates stated that ultrasonographic findings can 
predict a massive hemorrhage in placenta previa45. Saitoh et al., 
demonstrated that the risk of massive antenatal hemorrhage is higher 
(83.3%) in cases  with an echo free space in the placental edge overlying  
 
 
 
 
19 
 
the internal os compared to other locations47. This echo free space was 
either a placental sinus or varices that developed in the decidual tissue. 
Ghi et al reported a possible association between the cervical 
length and the risk of preterm hemorrhage in complete placenta previa46. 
Stafford et al., demonstrated that a third trimester cervical length of 3cm 
or less was associated with an increased of hemorrhage and that 
Tocodynamometer evidence of regular uterine contractions was more 
common in patient with short cervix. 
Oyelese and Smulian reported that contractions and 
cervicaleffacement, dilatation during third trimester can cause separation 
of the placenta leads to minimal bleeding19. This bleeding may stimulate 
further placental separation and unavoidable bleeding. 
HEMORRHAGE DURING CAESAREAN SECTION: 
Risk factors are  
    Advanced maternal age 
    H/O previous caesarean section 
    Anterior placenta 
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    Placenta located on the previous uterine scar 
    The presence of lacunae in the placenta 
    Sponge like finding in the cervix 
    Lack of a clear zone 
    Adherence of the placenta 
DOPPLER VELOCIMETRY: 
D.W.Kwak et al., reported that uterine artery doppler RI is reduced 
in placenta accreta compared with placenta previa. Low uterine artery 
Doppler RI is independent risk factor of placenta accreta in a placenta  
previa patient. 
BIOCHEMICAL MARKERS: 
1.MATERNAL SERUM ALPHA FETOPROTEIN: 
Also known as alpha-1-fetoprotein, alpha-fetoglobulin or alpha 
feto protein. It is  encoded by the AFP gene. The AFP gene is located on 
the q arm of chromosome 4. AFP is a major plasma protein produced by 
the yolk sac and the liver during fetal development. It is thought to be the 
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fetal form of serum albumin. AFP binds to copper, nickel, fatty acid and 
bilirubin and found in monomeric, dimeric and trimeric forms. 
Structure: 
  AFP is a glycoprotein of 591 amino acids and a carbohydrate moiety. 
Function: 
 AFP is the most abundant plasma protein found in the human foetus. 
Plasma levels decreases rapidly after birth but start decreasing prenatally 
at the end of the first trimester. Normal adult level is achieved by the age 
of 8 – 12 months. The function of AFP in adult humans is unknown. 
Maternal serum levels: 
In pregnant women, fetal AFP levels can be monitored in fetal 
urine. AFP is cleared strongly from the kidneys allowing urinary AFP 
tend to mirror fetal serum level. MSAFP level are much lower but 
continue to rise until about 32 weeks. 
       MSAFP is elevated in spontaneous abortion, gestational 
Hypertension, pre-elampsia, chronic Hypertension, preterm delivery, 
IUGR and PPROM. Katz et al., reviewed that  unexplained MSAFP 
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elevation is associated with poor maternal and/or fetal outcome,  probably 
as a consequence of placental injury48. 
  Simpson confirmed the association between second 
trimesterelevation of MSAFP  levels and the adverse outcome49. 
Ramusconcluded that women with elevated MSAFP level have 
associatedhyperechogenic placenta and maternal and fetal 
complications50.  
Koster EL et al, concluded that there is an association between 
increasing MSAFP and greater likelihood of persistent placenta previa. 
An MSAFP value less than 1 MOM is associated with a reduction in the 
risk of persistence of previa to delivery20. 
  EL Butler et al, concluded that women with placenta previa and 
high MSAFP more than 2 MOM are at increased risk of bleeding in early 
third trimester and preterm birth21. 
2.CELL FREE FETAL DNA 
Lo et al., discovered the presence of increased cell free DNA in 
plasma measured by real time quantitative PCR assay. In addition they 
analyzed the Y chromosome specific SRY sequence to quantify the 
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number of genome equivalent/ml of plasma in women carrying male 
foetus and they concluded that foetal cell free DNA in plasma and 
genome equivalent per ml as significantly elevated in placenta previa 
patients with placental invasion. It has been suggested that invasion of 
trophoblast into the uterine muscles of these patients produces increased 
placental concentration of cell free foetal DNA because of the destruction 
of trophoblast by immune system42. 
Jimbo and Sekizawa et al, reported that the concentration of free 
DNA in the plasma might be a useful marker to follow patients with 
retained placental tissue after delivery43. 
CREATINE KINASE   
It is used as a biochemical marker of placenta increta and percreta. Ophir 
E et al reported that in placenta previa patients with ultrasonographic 
findings of adherent placenta, unexplained elevation of creatine kinase in 
serum  should alert the clinician regarding the possibility  of placenta 
increta and percreta.44 
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CLINICAL PRESENTATION 
The most characteristic event in placenta previa is sudden onset of 
painless apparently cause less and recurrent hemorrhage. Fortunately 
initial bleeding is rarely profuse.  Most women with placental previa do 
not bleed until the onset of labour especially central placenta previa. 
Asymptomatic cases may be detected by sonography. 
Vaginal bleeding is mostly of maternal origin. However the fetal 
component could be significant if some disruption of the villi occur.  
         Crenshaw et al., in 1973 reported that one third of patient with 
placenta previa have their first bleeding episode before 30 weeks, other 
third at 30-35 weeks  and another third after 36 weeks22. The mean 
gestational age at the first bleeding episode is 29.6 weeks.                 
         Fetal blood loss may be detected by fetal heart rate monitoring.  A 
simple test by Loendershoot in 1979, take 2 test tubes with 5 ml of tap 
water in each and add 10 ml of KOH. In one tube add 3 drops of vaginal 
blood and in another tube add 3 drops of maternal blood and wait for 2 
minutes. If vaginal blood contains fetal blood cells the solution will be 
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pink in color. The other tube with maternal blood will have green 
yellowish brown color. 
Foetal malpresentation like breech or transverse or 
compoundpresentation accounts to 30%. In case if it is vertex 
presentationthey are in persistent occipitoposterior or transverse 
position(15%). 
Generally the patient is anaemic. 
 According to M C Shan et al., 1985 the incidence of pretermdelivery, 
number of bleeding episodes, severity of the bleeding, units of blood 
transfusion needed are higher for patient who had bleeding episodes 
before 28 weeks of gestation. 
CLINICAL EXAMINATION 
Generally the size of the uterus is corresponding to the period of 
gestation.Uterus feels soft and relaxed without  tenderness.The head is 
floating in contrast to the period of gestation.Persistent displacement of 
foetal head is  suggestive of placenta previa.The head cannot be pushed 
down into pelvis.Fetal heart sound is usually present unless there is a 
major separation ofplacenta with patient in exsanguinated state. 
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Slowing of fetal heart rate while pressing the fetal head down into the 
pelvis, which recovers promptly as the pressure is released -suggestive of 
low lying placenta posterior type. It is known as stallworth sign. 
 VULVAL INSPECTION  
Only inspection is to be done to assess whether the bleeding is 
stilloccurring or not, character of the bleeding and amount of bleeding. 
Inplacenta previa the bleeding is bright red since the bleeding occurs 
fromthe separated retro placental sinuses close to the cervical os. 
DIGITAL EXAMINATION 
No justification for digital vaginal examination in patients 
withpainless vaginal bleeding. 1 in every 16 examinations produces 
amajor hemorrhage and 1 out of every 25 examination result 
inhypovolumic shock. Accuracy of digital pelvic examination in the 
diagnosis of placenta previa is only 69%. 
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DIAGNOSIS 
1.RADIOLOGICAL DIAGNOSIS 
Placentography - localisation of placenta. 
Trans abdominal sonography 
It is the simplest,safest and accurate method of placental 
localization.Routine placental localization is done as a part of the 
anomaly scanat 20-22 weeks of gestation. According to Laing 1996, the 
accuracy oftrans abdominal sonography is 96%23.  
False negative results are due to bladder distension and 
myometrialcontraction. Poor imaging could be due to maternal obesity 
andposteriorly placed placenta.  
The reason for poor imaging in a posteriorly placed placenta are dueto 
acoustic shadows from the fetal presenting parts which obscuresthe 
placental view and there is no anatomical landmark posteriorly. 
A positive case should be subjected to repeated scan at 34 weeks or 
earlier for detection of placental migration. A low lying placenta is more 
common in early pregnancy because the lower segment does not exist.     
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The apparent placental migration is due to enlargement of the 
uppersegment and formation of the lower uterine segment.  
Comeau and associates and Ruparelia and Chapman reported that 
themore advanced the pregnancy, the more accurate the diagnosis of 
theplacenta previa based on sonography24. False positive rate in 
transabdominal ultrasound is of 7% and false negative rate is 8%. 
Inultrasound the length of lower uterine segment is less than 1 cm at 
20weeks and is more than 5 cm at term due to progressive enlargement 
ofthe uterus. 
 Transvaginal sonography 
The use of transvaginal sonography has improved the 
diagnosticaccuracy of placenta previa. 
 Timor-Tritch and Yunis 1993 shown that transvaginal sonogram 
tobe safe25. Farine and associates 1988 were able to visualise the 
internalcervical os in all cases using the transvaginal technique in contrast 
only by 70% in transabdominal method26. 
 Smith in 1997 and Taipale 1998 compared both imaging and 
found that transvaginal technique is superior and safe27. The accuracy is 
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higher in transvaginal ultrasound in evaluation of vaginal bleeding during 
pregnancy than transabdominal scan26 (farine et al., 1988). 
 Endovaginal ultrasound has a positive predictive value of 93.3% 
and negative predictive value of 97.6% for the diagnosis of placenta 
previa. A placental edge exactly reaching the os is described as 0 mm. 
When the placental edge reaches or overlaps the internal os on 
 TVS between 18 – 24 weeks of gestation, a follow-up scan for placental 
localization in the third trimester is recommended. Overlap of more than 
15 mm is associated with an increased likelihood of placenta previa at 
term. Overlap of more than 20 mm at any time is highly predictive of the 
need of caesarean section. 
Dashe and co-workers concluded that in 34% of cases, placenta 
previa that was diagnosed at 20-23 weeks persisted at delivery, whereas 
73% of those, present at 32 – 35 weeks persisted at delivery28. 
Trans perineal sonography 
Trans perineal or trans labial ultrasound using a trans 
abdominalprobe can improve the diagnostic accuracy of transabdominal 
ultrasoundand can be used as an alternative for TVS if TVS not available. 
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Hertzberg and colleagues in 1992 reported that trans 
perinealsonography was accurate to localise placenta previa29. 
Rani and associates 2007 demonstrated that trans perineal 
sonography had 98%of positive predictive value and 100% negative 
 predictive value30. 
2.Color Doppler flow study  
Recent guidance from RCOG recommends that patients with a 
previous CS and an anterior placenta previa should have color flow 
doppler as investigation of choice. 
Prominent venous flow in the hypo echoic areas near the cervix is 
consistent with the diagnosis of placenta previa. 
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3.Magnetic resonance imaging 
 It is non invasive method without any use of ionizing radiation. Quality 
of placental imaging is excellent. But it is unlikely that MRI will replace 
sonographic scanning for routine evaluation in the near future. But 
Palacious Jaraquemada and Bruno 2005 stated that MRI more useful for 
diagnosis of placenta accreta than placenta previa31. 
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ii. CLINICAL DIAGNOSIS 
By internal examination (double setup examination) 
Direct visualisation during caesarean section  
Examination of placenta following vaginal delivery 
DOUBLE SETUP EXAMINATION 
Examination  done  in an operating  room provides the most 
accurate assessment of the relationship between the lower edge of the 
placenta and the cervical os. This approach is contraindicated by active, 
profuse hemorrhage mandating immediate delivery. 
Procedure: 
   After catheterizing the bladder two fingers are gently introduced 
into the vagina with care taken to avoid the cervical os. Each vaginal 
fornix is palpated in turn to feel whether there is placenta between the 
presenting part and the finger. If placental tissue is present, a sensation of 
“bogginess” is felt. If the four fornices are empty, then the index finger is 
gently introduced into the cervical os and the surroundings, felt for the 
placental edge. 
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LABORATORY INVESTIGATIONS  
Complete Blood Count 
Blood grouping and typing  
Liver and renal function test 
Coagulation profile  &ECG 
DIFFERENTIAL DIAGNOSIS 
  1.  Abruptio placenta 
  2. Cervical polyp 
  3.Cervical Carcinoma 
  4.Circumvallate placenta 
COMPLICATIONS 
Maternal complications 
1. During pregnancy 
          -antepartum hemorrhage  
          -malpresentation 
          -preterm delivery 
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2. During labour 
           -early rupture of membranes  
           -cord prolapse 
           -slow dilatation of cervix due to attachment of placenta on the 
lower segment 
           -intrapartum hemorrhage 
           -increased incidence of operative interference  
           -postpartum hemorrhage  
           -imperfect retraction of the lower uterine segment upon which the 
placenta is implanted 
           -large surface area of placenta with atonic uterus  
           -morbidly adherent placenta 
           -trauma to cervix and lower segment because of extreme softness 
and vascularity 
           -retained placenta 
           -anaesthetic and surgical complications 
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           -air embolism 
           -coagulation defects 
Coagulopathy is rare with placenta previa even when there is 
extensive  separation from the implantation site. Presumably 
thromboplastin which  incites intravascular coagulation that commonly 
present in abruption  placenta readily escapes through the cervical canal 
rather than being  forced into the maternal circulation. Wings and 
colleagues 1996  reported that there is no evidence of coagulopathy in 
placenta previa  patients with bleeding episodes32. 
-Placental invasion 
Placenta previa is associated with placenta accreta, increta and 
percreta  is due to absence or deficiency of nitabuch layer or the 
spongiose layer  of the deciduas and will dealt in detail later.   
Feotal complications  
-Low birth weight babies are common around 15% due to either  
spontaneous or induced preterm labour. 
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Fetal growth restriction is due to repeated small bouts of hemorrhage  
when patient is on expectant line of management which causes chronic  
placental insufficiency (16%). 
    -Birth asphyxia 
    -Intrauterine death 
    -Birth injuries 
    -Congenital malformation is 2-4 times more common. 
 There are no specific abnormalities associated with placenta previa but  
most commonly associated with central nervous system, cardiovascular,  
respiratory and gastrointestinal systems. 
MATERNAL  OUTCOME: 
The possible reasons for maternal mortality are 
    -postpartum hemorrhage 
    -anaesthetic and surgical complications 
    -air embolism 
   -ascending infection 
   -placenta accreta 
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A rapid reduction in maternal mortality rate due to placenta previa 
was  achieved during the second half of the 20th century. Oyelese and 
Sumulian in 2006 reported that MMR is increased by 3% due to placenta 
previa19. Emach reported that MMR is 3 in 2003-2005 due to hemorrhage 
that occur in placenta previa. Crenshaw et al., 1973 reported that the 
number  of units of blood needed per patient in total, partial and marginal  
placenta previa is 4.7, 3.6 and 2.5 units respectively22. 
FETAL OUTCOME: 
Cotton and colleagues reported perinatal mortality rate of 100% at 
less  than 27 weeks, 19.7% at 27 to 32 weeks, 6.4% at 33 to 36 weeks and  
2.6% after 36 weeks in 198033. In recent years the overall PMR reduced   
due to improved neonatal care.  Perinatal mortality rate is higher with 
earlier bleeding, greater amount of  bleeding and greater extent of 
placenta previa.  
According to the data collected by Crenshaw et al., 1973 perinatal  
mortality is mainly due to induced preterm delivery because of  
hemorrhage22. Salihu and associates in 2003 reported that neonatal 
mortality rate is  increased by 3 fold in placenta previa34. Ananth CV and 
associates in 2003 reported that increased risk of neonatal death even in 
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term pregnancy with  placenta previa35. Brar and colleagues in 1988 
stated that the incidence of fetal growth restriction is nearly 20%51. Crane 
JMG and co workers in 1999 stated that there is no increased incidence of 
IUGR after controlling the gestational age36. Ananth and associates in 
2001 reported that association between placenta previa and low birth 
weight was due to preterm birth and to lesser extent from growth 
restriction37.  
MANAGEMENT OF PRETERM PREGNANCY  
Management with preterm foetus without persistent active uterine 
bleeding need only close monitoring. Some women needs prolonged 
hospitalisation. Ideal management of placenta previa patients is 
hospitalisation, but selective patients can have home monitoring. 
According to Mouer 1994, Neilson 2003, in properly selected patients no 
need for hospitalisation38.  
Drost and Keil reported that there are 50% reduction of 
hospitalisation and 40% reduction in cost expenditure in outpatient 
management39. Wing and colleagues concluded that there are no 
difference in maternal or foetal morbidity rates with outpatients vs 
inpatients observation40.  
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GENERAL MANAGEMENT 
Prevention  
1. Adequate ante natal care:  
Observational studies so far suggest that in women with elevated MSAFP 
at 15-20 weeks,in ultrasound if placenta  encroach on the  cervical 
os,thick placenta inferiorly, or show turbulent flow at their  lower margin 
are mostly associated with APH, needs close monitoring. 
2. If antenatal ultrasonogram  at 20 weeks shows low lying placenta 
then  do repeat ultrasound at 34 weeks to confirm the diagnosis. 
3. Should not ignore the presence of “warning hemorrhage”. 
4. Do Color flow Doppler ultrasound to detect the placental invasion.  
 
Management depends on  
1. Mother’s condition, evidenced by the degree of obstetric     
hemorrhage  
2.Foetal condition depends on gestational age  
3.The ability of neonatal unit to handle an infant of lesser gestational age 
4.Management protocol depends on severity of bleeding. 
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CLASSIFICATION OF SEVERITY OF BLEEDING41 (Gutierrez, 
Reines HD, Wult Gutierrez ME et al.,) 
Class  1(MILD) 2(MODERATE) 3(SEVERE) 4(SEVERE) 
Blood loss <750 ml, 
<15% 
750-1000ml, 
15-30% 
1500-2000ml,  
30-40% 
>2000ml. 
>40% 
Pulse 
rate/min 
100 100-120 120-140 140 
Blood 
pressure 
Normal decreased Decreased Decreased 
Respiratory 
rate/min 
14-20 20-30 30-40 40 
Urine output 30ml 20-30 5-15 Negligible 
CNS 
symptoms  
Normal anxious Confused Lethargic 
 
TREATMENT ON ADMISSION  
Immediate care 
1. Asses the amount of blood loss  
2. Arrange Rh compactable blood for transfusion 
3. A large bore IV canula is inserted and NS infusion started 
4. Gentle abdominal palpation to ascertain any uterine tenderness  and 
auscultate for fetal heart sound. 
5. Local inspection of vulva for the presence of active bleeding per 
Vaginum. 
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MANAGEMENT OF PATIENTS WITH MILD BLEEDING: 
Conservative line of management: 
Macafee and Johnson expectant treatment 52(Silver R, Depp R, 
Saggagha RE et al.,) This is an attempt to improve the fetal salvage 
without increasing undue  maternal hazards. It should be done in place 
where blood is available  whenever required and facilities for caesarean 
section should be  available throughout 24 hours. 
Ideal cases  are 
1. Mother is in good healthly status (Hb >10 g%, HCT >30%). 
2. Duration of pregnancy is <37 weeks. 
3. Active rapid vaginal bleeding is absent. 
4. Fetal well being is reassured. 
CONDUCT OF EXPECTANT MANAGEMENT 
1. Bed rest with limited bathroom privileges are usually allowed. 
2. Intercourse, douching and vaginal suppositories are avoided. 
3. Stool softeners are appropriate to avoid straining at defecation. 
4. Basic investigations to be done 
5. Periodic inspection of vulval pads and foetal surveillance using 
ultrasound in 2-3 weeks interval. 
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6. Blood loss is replaced with blood products. 
7. Gentle cusco’s speculum examination is made to exclude the 
8.  local cervical and vaginal lesions for bleeding 
9. Use of tocolytics: Can be given for vaginal bleeding patients. 
 Besinger et al., 1995 reviewed that the use of tocolysis in 
symptomatic  placenta previa women is significantly associated with 
prolongation of  pregnancy and increased birth weight53. 
Drug of choice is Nifedipine 10-20 mg orally every 4-6 hrs. Tocolysis  
can be continue until delivery. Tower and associates suggested no  
increased mortality and morbidity associated with tocolytic use in a  
tertiary care54. 
10.Use of cervical encerclage to reduce bleeding and to prolong 
pregnancy is not useful (RCOG 2005). 
Lovset 1959, Von Friesen (1964,1972), Sadauskas et al., 1982  
demonstrated a significantly greater prolongation of pregnancy in  
women treated with cerclage than in women managed conservatively55.  
Thus cervical cerclage limits the development of the lower uterine  
segment, which occurs in advancing gestation and the effect of uterine  
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contractions, in turn avoids the partial detachment of the placenta from  
the lower uterine segment. 
Arias 1988 reported that cerclage patients had significantly better  
outcomes as more advanced gestational age at delivery, greater birth  
weight, less neonatal complications.  Cobo et al., 1998 concluded that 
there is no significant difference in  maternal and fetal outcome in 
patients with cerclage and expectant  management56.  
Neilson et al 2003 found that cervical cerclage may reduce the risk of  
delivery before 34 weeks and that of the birth weight less than 2 kg or  
having a low 5 minute APGAR score57.  
11.Rh immunoglobulin should given to all Rh negative women 
 12.Glucocorticoids. 
Multiple studies have shown that 50% reduction in incidence of hyaline 
membrane disease in preterm infant born after a mother received 
glucocorticoids. The time necessary for this effect can be as little as 24 
hrs or as much as 72 hrs.  
Liggins and Howie 197 stated that the reduction of HMD was confined to 
preterm babies delivered within 1-7 days of maternal glucocorticoid 
treatment58. 
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Medications used are  
a) Nifedipine 10-20 mg orally every 4-6 hrs. 
b) Betamethsone 12 mg im every 24 hrs for 2 doses. 
     c) Feso4 325 mg orally three times daily. 
     d) Stool softeners, high residue diet. 
Ideally expectant management should be given in hospital care and is 
carried up to 37 weeks of gestation. 
Expectant management can be given at home in certain patients 
  -who live very close to hospital 
  -24 hours transportation is available 
  -bed rest assured 
  -patients and her attenders are well motivated about the risk. 
           -72 hrs of inpatient observation without vaginal bleeding 
           -reactive Non Stress Test at the time of delivery 
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DEFINITE MANAGEMENT (DELIVERY) 
INDICATIONS: 
1. Bleeding occurs at or after 37 weeks of gestation 
          2. Patient is in labour 
          3. Bleeding is continuing and of moderate degree 
          4. Patient is in exsanguinated state on admission. 
          5. Baby is dead or known to be congenitally deformed. 
Vaginal delivery may be considered where placental edge is clearly 
2-3  cm away from the internal os. Caesarean delivery is done for all 
women with sonographic evidence of  placenta previa where placental 
edge is within 2 cms from the internal  os. It is mainly indicated if it is 
thick more than1cm and posterior (RCOG  2005). 
Elective caesarean delivery is ideal because emergency delivery 
has more negative impact on maternal and perinatal outcome, 
independent  of gestational age. Cotton and colleagues found that 27.7% 
of infant delivered emergently had anaemia compared with 2.9% 
delivered electively. 
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Vaginal delivery is induced by low rupture of membranes using long 
 kochers forceps in type 1 and type 2 placenta previa.  
ARM followed by oxytocin drip to be started if aminotomy fails to 
stop  bleeding or fail to initiate labour, caesarean section is performed. 
Active management of 3rd stage of labour to be done along with  
Inj. Methergin 0.2 mg given intravenously while delivering ant shoulder.. 
 
PRECAUTIONS DURING CEASARIAN SECTION  
       -done by senior obstetrician 
       -regional blockage may be used 
        -if the patient is in shock stage and the bleeding continues the 
operation has to be performed immediately with restorative measures. 
TYPE OF OPERATIONS: 
-  Lower uterine caesarean section is appropriate if the presenting  
part is easily accessible and the lower uterine segment has developed  
enough to allow a generous incision 
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-classical caesarean section provide greater flexibility in the 
approach to deliver the baby and less trauma to the foetus. 
Important points in lower segment approach are 
Most commonly lower segment transverse incision is possible, when 
difficulties occur the transverse incision may  be converted to  an inverted  
T, J or U shaped incision. 
To avoid foetal bleeding which may result from a transverse incision with  
anterior placenta or when the lower segment is nonexistent or is very  
vascular, a vertical incision (classic) or De Lee incision is employed.  
Scott did not justify with these incisions, because of long term  
consequences. 
In transverse incision of the uterus with anterior placenta  two  
approaches are available: 
1. Going through the placenta 
2. Defining its edge and going through the membranes  above or 
below the placenta. 
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Myerscough recommends against cutting or tearing through the placenta  
because of the inevitable foetal blood loss. Ward 2003 described a 
surgical method in which a cleavage plane is  developed following the 
uterine incision. The operator undermines the  placenta towards the 
closest edge until the membranes are palpable  and they are then ruptured 
with the foetus and delivered around the  intact placenta59. 
.Due to poor contractile capacity of the lower uterine segment there may  
be uncontrollable hemorrhage following placental removal. If the  
bleeding from the placental bed is not controlled by the conservative  
methods other methods have to be attempted. 
    1. Over sewing the implantation site with 0 chromic suture. 
    2. Bilateral uterine artery and internal iliac artery ligation can be done. 
Cho and colleague 1991 reported that interrupted 0 chromic suture 1 cm  
apart and forming a sutured circle around the bleeding portion of the  
lower segment can be done. 
Druzin 1989 described that uterine cavity packing with gauze pack to  
arrest hemorrhage and the pack was removed 12 hours later by trans  
vaginal route60. 
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Intramyometrial injection of prostaglandin F2 alpha is useful. Knight 
2007 reported that in women with placenta previa if placenta is  
implanted anteriorly in the site of previous uterine scar there is a  
increased likelihood of placenta accreta and she needs hysterectomy as  a 
last resort61. 
MANAGEMENT OF PATIENTS WITH MODERATE BLEEDING: 
Delivery by caesarean section should be performed if the 
pregnancy  is 36 weeks or more. If the pregnancy is between32 and 36 
weeks it is  necessary to evaluate the fetal lung maturity as soon as the 
acute  bleeding episode subsides and the patient’s condition is stabilized.  
Rapid test for assessing fetal pulmonary maturity is amniotic fluid 
is  lecithin to sphingomyelin ratio (L/S). If the L/S ratio greater than 2, 
the  foetus should be delivered. If lungs are immature start on steroid  
therapy.   
If the patient is stable give her expectant management.  In unstable 
patient alert paediatrician regarding imminent delivery as the  risk of 
developing Respiratory distress syndrome of the new born is  high. 
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MANAGEMENTOF PATIENT WITH SEVERE BLEEDING: 
Constant observation and monitoring the vital parameters 
Administration of intravenous fluids  
Transfusion therapy 
Assessment of renal function 
Assessing the foetus 
Delivery 
 
INVESTIGATIONS 
CBC 
Blood grouping and typing 
Serum electrolytes 
Glucose 
Creatinine 
Blood urea nitrogen 
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DIC profile -  Serum fibrinogen 
                    -PT, PTT 
                    -Platelet count 
                    -D-dimer 
                    -Fibrin degradation products. 
Intravenous fluids 
One or two large bore canulas should be inserted. One litre of crystalloid  
solution results in 250 ml of intravascular volume expansion. 
Transfusion theory 
Packed red cell transfusion is an essential component in the treatment of 
obstetrical hemorrhage. One important danger is transmission of 
infections like hepatitis C and B, HIV, CMV. Fortunately the probability 
of infection transmission is less (Brecher and Hay 2005) after introducing 
nucleic acid amplification testing for donated blood. In obstetrical 
hemorrhage, ideal method to select blood for potential  transfusion is 
“type and screening” rather than “type and cross match” 
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 In rare circumstances type O Rh negative packed cell transfusion  should 
be given.  To overcome platelet depletion in massive blood transfusion 
(10 units or  more within 24 hrs) the best approach is to transfuse 1 unit 
of platelet  which obtained from a single donor. For clotting factor 
deficiency  transfuse FFP in the ratio of 1:4 (1 FFP:4 PC)  Yamada and 
co-workers suggested some benefit in autologous   transfusion of placenta 
previa patients, but needs further studies.   
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PLACENTA ACCRETA, INCRETA, PERCRETA 
DEFINITION 
PLACENTA ACCRETA 
The term placenta accreta is described if any implantation of placenta in  
which there is abnormally firm adherence to the uterine wall as the  
consequence of partial or total absence of the decidua basalis and  
imperfect development of the fibrinoid or nitabuch layer.  Histology 
shows that the trophoblast has invaded the myometrium  without any 
intervening decidua. 
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PLACENTA ACCRETA - placental villi are attached to the 
myometrium. 
PLACENTA INCRETA - Placental villi invade into the myometrium. 
PLACENTA PERCRETA - Placental villi penetrate through the 
myometrium. 
TOTAL PLACENTA ACCRETA - Abnormal adherence of all lobules 
of the placenta 
PARTIAL PLACENTA ACCRETA - Abnormal adherence of only a 
few to several lobules  
FOCAL PLACENTA ACCRETA - Abnormal adherence of all or part 
of a single lobule may be involved  
Benirschke and colleagues 2006 reported that histological diagnosis 
cannot be made from the placenta alone and the entire uterus or curettings 
with myometrium are necessary for histopathological confirmation62. 
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INCIDENCE: 
   The incidence of placental invasion has increased over few decades,  
because of the increasing caesarean section rate. ACOG 2002 reported  
that placenta accreta complicates 1 in 2500 deliveries. Stafford and  
Belfort 2008 cite the incidence is 1 in 2500 in the 1980s,1 in 535 in   
2002, and 1 in210 in 2006. 
 Zelop and colleagues 1996 reported that placenta accreta has been the  
leading cause of intractable postpartum hemorrhage requiring  emergency 
peripartum hysterectomy63. 
ASSOCIATED CONDITIONS:  
Previous caesarean delivery scar or after uterine curettage. Here the 
decidual formation is defective. Fox reported that 1/3 of cases  had 
placenta previa, 1/4 had a prior caesarean delivery, 1/4 had  previous 
curettage and 1/4 were gravida 6 and above64.  Zaki and associates 1990 
found that 10% of placenta previa had  associated placenta accrete.      
Hardardottir and colleagues 1996 observed 50% of women with a  
previous caesarean delivery had adherent placenta in myometrial fibres  
detected microscopically65 
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 The risk for accreta was increased 8 fold when MSAFP level more  than 
2.5 MOM and it was increased 4 fold when the maternal free   beta-HCG 
levels more than 2.5 MOM and it was increased 3 fold when  maternal 
age more than 35 years. 
 CLINICAL COURSE  
In the 1st trimester abnormal myometrial invasion may manifest as 
a  caesarean scar pregnancy 66(Ash and associates 2007),  Rotas and 
colleagues 2006 reported that this type of ectopic pregnancy  is increasing 
in frequency67. If pregnancy advances placental villi at the  site of a 
previous caesarean scar may lead to uterine rupture before  labour68stated 
by Liang and co workers 2003.   
Antepartum hemorrhage with placenta accreta.  
PREDICTION OF PLACENTAL ADHERENCE: 
ULTRASONOGRAPHIC PREDICTION: 
1. Irregularly shaped placental lacunae within the placenta. 
2. Thinning of myometrium overlying the placenta. 
3. Loss of retro placental clear zone. 
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4. Protrusion of the placenta into the bladder. 
5. Increased vascularity of uterine serosa and bladder interface. 
Pasto et al, suggested that a lack of retro placental clear space 
detected  using ultrasonography may be abnormal sign of placenta accreta 
and  can be detected as early as 12 weeks. 
Comstock et al., found that at 15-20 week of gestation, the 
presence of lacunae in the placenta was the most predictive sign of 
accreta.. Finberg and Williams reported the number of lacunae was 
associated  with complications related to placental adherence.  
 Yang et al. classified the sonographic finding of intra placental 
lacunae  into 4 grades. He concluded that the presence of > than grade 2  
lacunae was strongly associated with placenta accreta. 
Hurton et al, reported that the areas with sponge like echoes were 
most  likely composed of clusters of richly developed blood vessels. 
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PERIOPERATIVE EVALUATION 
Lam and colleagues 2004 found that antepartum sonography was only  
33% sensitive for detecting placenta accreta. 
 Twickler and colleagues 2000 reported two factors are highly predictive  
of myometrial invasion69 . 
1. Distance <1 mm between the uterine serosa-bladder interface and  
the retro placental vessels. 
2. Identification of large intra placental lakes . 
These findings had 100% sensitivity and positive predictive value of 78%  
Chou and co workers 2001 concluded that successful use of 3D color  
Doppler imaging for diagnosis of placenta percreta. 
MR imaging is used as an adjuvant to sonography in diagnosing accreta. 
Lax and co workers 2007 suggested that 3 MRI findings to diagnose 
accreta70.  
1. Uterine bulging 
     2. Heterogeneous signal intensity within the placenta 
     3. Presence of dark intra placental bands on T2-weighed imaging. 
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MANAGEMENT: 
Thorough preoperative assessment allows better planning and 
transfer  these patients for tertiary .care.  
Pre operative arterial balloon tipped catheter placement into the 
internal  iliac arteries  decrease the blood loss during placental delivery. 
Alternatively the catheters can be used  to embolize the arterial 
sites YU and colleagues 2009 reported favourable outcome with uterine 
artery  embolization71. 
Greenburg and collegues 2007 adviced  to take necessary 
precaution  while attempting embolization in order to prevent thrombosis 
of common  and external iliac vessels72 . 
DELIVERY OF PLACENTA 
 Problems associated with delivery of placenta depends on 
implantation  sites, depth of myometrial penetration and number of 
lobules involved.  Focal placenta accreta with implantation in upper 
uterine segments may  be unrecognised and it may be the cause of 
postpartum hemorrhage.  Benirschke and Kaufmann 2006 reported that 
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focal placental accrete  may be the cause for formation of placental 
polyp73. 
  When there is extensive invasion of placenta into the myometrium 
leads  to the profuse hemorrhage on attempting placental delivery which 
can  be tackled with immediate blood replacement and prompt 
hysterectomy. With total placenta accreta there may be little or no 
bleeding after the   delivery of the baby and at times traction on umbilical 
cord causes  uterine inversion.  
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Usual attempt of manual removal of placenta do not succeed 
because of  absence of cleavage plane between placenta and the uterine  
myometrium. For this conservative management like manual removal of  
as much placenta as possible followed by uterine packing can be done,  
but mortality with these treatment is 25% 64(Fox 1972).So safest  
management is total hysterectomy. If not possible go for subtotal  
hysterectomy. 
Another method during caesarean section is to leave the entire 
placenta  insitu without attempting to extract it and to close the caesarean  
hysterotomy incision74 (Worley and associates, 2008) Several scenarios 
have described about methotrexate injection given at  the time of surgery. 
Kayem and colleagues 2002, Lee and co workers  2008 also performed 
pelvic arterial embolization75.  
Other measures are Uterine or internal iliac artery ligation and 
Balloon occlusion or embolization of pelvic arteries.   
Karam and colleagues 2003 described the use of argon beam  
coagulation for haemostasis in a woman with placenta percreta and  
bladder invasion.   
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Keyam, Henrich  and co workers  showed in few cases there are  
spontaneous  resorbtion of placenta.   
Hay 2008, Lee 2008, Nijman 2002 concluded that hysterectomy either  
planned or prompted for hemorrhage  or infection is performed  several  
weeks postpartum when blood loss may be less torrential 
MANAGEMENT OUTCOME 
Eller and co workers 2009 reported that preoperative identification 
of  adherent placenta with scheduled caesarean hysterectomy without  
placenta removal was associated with significantly reduced morbidity  
when compared with those of attempted placenta removal76.   
Timmerman and co workers 2007 reviewed that the conservative  
management of leaving the placenta insitu with either adjuvant  
methotrexate or uterine artery ligation as fertility conservation may  
prevent massive hemorrhage thus the overall success rate as infertility  
prevention was 80%77. 
Serial serum beta HCG measurements were not found to be 
predictive  but many authors recommend serial imaging with sonography 
or MRI  for follow up. 
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The main complication of conservative management is vaginal 
bleeding  and thus 15% of these groups go for hysterectomy in view of 
controlling  hemorrhage.   
REVIEW OF LITERATURE FOR MSAFP: 
1.Unexplained elevation of MSAFP  and placenta previa. 
Waller et al 1996 of north middle sex university hospital NHS 
trust. Obstet  Gynecol 1996,88:816-22 
Unexplained raised MSAFP has been associated with adverse 
pregnancy outcome such as intrauterine fetal growth  restriction,  
preeclampsia, preterm birth and placental complication includes  
placental abruptio as well as placental invasion disorder like accreta,  
increta, percreta. 
The incidence of placenta accreta was about 1 in 7000 pregnancies,  
with increasing trend due to increased caesarean birth. 
Recognised  risk factors  are placenta previa, uterine surgery, 
uterine  curettage, multiparity, advanced maternal age (Hung etal 1999). 
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 Gagnon et al 2008 suggested that the combination of raised 
MSAFP and placenta previa should strength the clinical suspicion of 
invasive  placental disorder. 
2. Increased likelihood of placenta accreta with persistent 
placenta  previa and raised MSAFP. 
Kupferminc MJ,Tamura RK,WigtonTR, et al. 
Obstet Gynecol 1993;82:266-9 
Kupferminc et al 1993 in a retrospective review of all patients who  
underwent emergency caesarean hysterectomy  reported that women  
with MOM>2.5 are at the higher risk of placenta accreta  and also of  
significant  blood loss with mean MOM >1.39.(Koster et al 2004).  
Gagnon et al 2008 recommended that when unexplained raised  
MSAFP  occurs in combination with 2nd or 3rd trimester placenta previa,  
a thorough assessment of the placental-uterine interface must be made. 
Needs multi disciplinary approach for delivery and also required  
appropriate counselling and consent for surgery to be taken. 
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3.placenta accreta/percreta/increta-a cause of elevated maternal 
serum alpha fetoprotein 
Zelop  C, Nadel A, Frigoletto jr, Pauker S, Macmillan M, Benaceraf BR 
Obstet Gynecol b1992 ,oct 80 (4),693-4. 
This study concluded that there is a significant  association  between  
elevated MSAFP and placenta accreta/percreta/increta  (P=0.017). Thus 
the patients with an unexplained elevation of MSAFP  as well as  
placenta previa may be at increased risk for abnormal placental  
adherence. 
4.placenta accreta is associated with elevated MSAFP 
Kupferminc MJ, Tamara RK, wigtonTR, Glassenberg  R, Socol ML 
Obstet Gynecol 1992;82:266-9. 
 Patients with placenta accreta, percreta, increta had an elevated 
 MSAFP with p value <0.001.Maternal estimated blood loss was also  
significantly greater in study group with p <0.0001. 
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Table : I A 
AGE GROUP * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
AGE GROUP 
 
<20 years  
 
 
 
21 -30 years  
 
 
 
 
>30 years  
1 Count 7 2 9 
% within AGE GROUP 77.8% 22.2% 100.0% 
% within PP PERSISTENCE 12.7% 4.4% 9.0% 
% of Total 7.0% 2.0% 9.0% 
2 Count 40 35 75 
% within AGE GROUP 53.3% 46.7% 100.0% 
% within PP PERSISTENCE 72.7% 77.8% 75.0% 
% of Total 40.0% 35.0% 75.0% 
3 Count 8 8 16 
% within AGE GROUP 50.0% 50.0% 100.0% 
% within PP PERSISTENCE 14.5% 17.8% 16.0% 
% of Total 8.0% 8.0% 16.0% 
 Total Count 55 45 100 
% within AGE GROUP 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
In this study antenatal mothers with age group between21-30 years was 75%. In these 
75 cases  40 (53.3%%) were not having persistent placenta previa and35 (46.7%) 
were having persistent of placenta previa.Age group less than 20 years were 9 
cases,more than 30 years were 16 cases. 
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Table : I B 
AGE GROUP * PP PERSISTENCE 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 2.132a 2 .344 
Likelihood Ratio 2.274 2 .321 
Linear-by-Linear Association 1.326 1 .250 
N of Valid Cases 100   
 
There is no statistical significance between persistent  placenta previa  and non 
persistent patients with respect to age distribution, since p value is 0.34. 
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Table : II A 
PARITY * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
PARITY 
 
Primigravida 
 
 
 
Mulitigravida  
 
1 Count 25 10 35 
% within PARITY 71.4% 28.6% 100.0% 
% within PP PERSISTENCE 45.5% 22.2% 35.0% 
% of Total 25.0% 10.0% 35.0% 
2 Count 30 35 65 
% within PARITY 46.2% 53.8% 100.0% 
% within PP PERSISTENCE 54.5% 77.8% 65.0% 
% of Total 30.0% 35.0% 65.0% 
 Total Count 55 45 100 
% within PARITY 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Among 100 antenatal women,35 were primigravida.out of these 35 women only 10 
(28.6%)  had persistence of placenta previa and out of 45 women with persistant 
placenta previa 22.2% were primigravida. 
Out of 100 antenatal women with placenta previa,65 were multigravida .Among these 
women 35cases(53%)  had persistent placenta previa and out of 45 women with 
persistent placenta previa 35cases (77.8%) were multigravida. 
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Table : IIB 
PARITY * PP PERSISTENCE 
Chi-Square Tests
 
Value 
df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 5.872a 1 .015   
Continuity Correctionb 4.895 1 .027   
Likelihood Ratio 6.025 1 .014   
Fisher's Exact Test    .020 .013 
Linear-by-Linear Association 5.813 1 .016   
N of Valid Cases 100     
 
There is a statistical  significance with multiparity and persistence of placenta previa 
since p value in this  study is 0.015.The bar diagram also shows the increased 
incidence of persistence of placenta previa at term is more with multiparous women. 
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Table : IIIA 
PREVIOUS LSCS * PP PERSISTENCE 
   
PP PERSISTENCE  
   
0 1 Total 
PREV.LSCS 0 Count 54 19 73 
% within PREV.LSCS 74.0% 26.0% 100.0% 
% within PP PERSISTENCE 98.2% 42.2% 73.0% 
% of Total 54.0% 19.0% 73.0% 
1 Count 1 19 20 
% within PREV.LSCS 5.0% 95.0% 100.0% 
% within PP PERSISTENCE 1.8% 42.2% 20.0% 
% of Total 1.0% 19.0% 20.0% 
2 Count 0 6 6 
% within PREV.LSCS .0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 13.3% 6.0% 
% of Total .0% 6.0% 6.0% 
3 Count 0 1 1 
% within PREV.LSCS .0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 2.2% 1.0% 
% of Total .0% 1.0% 1.0% 
 Total Count 55 45 100 
% within PREV.LSCS 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Out of 100 cases of placenta previa 27 cases were prior caesarean delivery cases  and 
73 cases were not having previous uterine scar. Among these 73 women of not having 
prior uterine scar only 19 cases (26%) were having persistent placenta previa  and 
these accounts for 42.2% in persistence group .Among  27 cases of prior caesarean 
delivery 26 cases (96%) had persistent placenta previa. 
Out of 20 cases of 1 prior caesarean delivery 19 cases were having persistence of 
placenta previa, accounts for 95% and in persistence group it accounts for 42.2%.6 
cases of previous 2 lscs and 1 case of previous 3 lscs  was reported in this study. 
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Table : IIIB 
PREVIOUS LSCS * PP PERSISTENCE 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 39.375a 3 .000 
Likelihood Ratio 45.979 3 .000 
Linear-by-Linear Association 32.693 1 .000 
N of Valid Cases 100   
 
There is excellent statistical  significance with previous lscs and persistence of 
placenta previa since p value is 0.000.In our Institution we get more cases of one 
previous lscs than 2 or more prior caesarean delivery.so the bar diagram shows 19 
cases of  one previous  lscs have persistant placenta previa  at term. 
 
 
 
 
 
72 
 
Table : IV A 
PREVIOUS ABORTION * PP PERSISTENCE 
   
PP PERSISTENCE  
   
0 1 Total 
PREV.ABOR 0 Count 40 30 70 
% within PREV.ABOR 57.1% 42.9% 100.0% 
% within PP PERSISTENCE 72.7% 66.7% 70.0% 
% of Total 40.0% 30.0% 70.0% 
1 Count 14 11 25 
% within PREV.ABOR 56.0% 44.0% 100.0% 
% within PP PERSISTENCE 25.5% 24.4% 25.0% 
% of Total 14.0% 11.0% 25.0% 
2 Count 0 3 3 
% within PREV.ABOR .0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 6.7% 3.0% 
% of Total .0% 3.0% 3.0% 
3 Count 1 1 2 
% within PREV.ABOR 50.0% 50.0% 100.0% 
% within PP PERSISTENCE 1.8% 2.2% 2.0% 
% of Total 1.0% 1.0% 2.0% 
 Total Count 55 45 100 
% within PREV.ABOR 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Out of 100 antenatal mother 30 cases had previous history of abortions and out of 
these  25 cases had previous history of 1 abortion. Out of 25,11 cases(44%) had 
persistence of placenta previa.3 cases had h/o 2 abortions and all 3 cases had 
persistence of placenta previa .In this study only 2 cases had previous h/o 3 abortions 
in which only one case had persistent previa. 
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Table : IV B 
PREVIOUS ABORTION * PP PERSISTENCE 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 3.827a 3 .281 
Likelihood Ratio 4.952 3 .175 
Linear-by-Linear Association 1.087 1 .297 
N of Valid Cases 100   
 
 
 
In this study there is no statistical significance in women with previous abortions and 
the persistence of placenta previa since the p value  is 0.281 and the pictorial 
representation also implies the same . 
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Table V A 
PREVIOUS VAGINAL DELIVERY * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
PREV.V.D 0 Count 32 38 70 
% within PREV.V.D 45.7% 54.3% 100.0% 
% within PP PERSISTENCE 58.2% 84.4% 70.0% 
% of Total 32.0% 38.0% 70.0% 
1 Count 13 5 18 
% within PREV.V.D 72.2% 27.8% 100.0% 
% within PP PERSISTENCE 23.6% 11.1% 18.0% 
% of Total 13.0% 5.0% 18.0% 
2 Count 9 2 11 
% within PREV.V.D 81.8% 18.2% 100.0% 
% within PP PERSISTENCE 16.4% 4.4% 11.0% 
% of Total 9.0% 2.0% 11.0% 
3 Count 1 0 1 
% within PREV.V.D 100.0% .0% 100.0% 
% within PP PERSISTENCE 1.8% .0% 1.0% 
% of Total 1.0% .0% 1.0% 
 Total Count 55 45 100 
% within PREV.V.D 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Out of 100  antenatal mothers 30 cases had previous h/o full term vaginal deliveries. 
.In these 30 cases,18 cases had previous h/o 1 FTVD,11 cases had 2 FTVD and only 1 
case have 3FTVD. 
With previous 1 FTVD  only 5 cases out of 18 cases(27.8%) had persistent placenta 
previa.2 cases of previous h/o 2 FTVD  had persistence of placenta previa. 
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Table V B 
PREVIOUS VAGINAL DELIVERY * PP PERSISTENCE 
 Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 8.610a 3 .035 
Likelihood Ratio 9.401 3 .024 
Linear-by-Linear Association 8.160 1 .004 
N of Valid Cases 100   
 
There is significant statistical correlation between the persistence of placenta previa  
and previous vaginal deliveries since the p value is 0.03 and it is more common in 
previous one vaginal delivery which has been shown in this bar diagram.(may be 
because our country is following   “two child norm”) 
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Table VI A 
MATERNAL OUTCOME * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
MATERNAL OUTCOME 
 
Good  
 
 
 
 
Adverse  
1 Count 55 0 55 
% within MATERNAL 
OUTCOME 
100.0% .0% 100.0% 
% within PP PERSISTENCE 100.0% .0% 55.0% 
% of Total 55.0% .0% 55.0% 
2 Count 0 45 45 
% within MATERNAL 
OUTCOME 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 100.0% 45.0% 
% of Total .0% 45.0% 45.0% 
 Total Count 55 45 100 
% within MATERNAL 
OUTCOME 
55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
This crosstab shows 45 cases out of 100 antenatal mothers   had maternal 
complications like antepartum hemorrhage, persistent placenta previa, complete 
placenta previa, preterm delivery, caesarean delivery and caesarean hysterectomy 
also. 
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Table VI B 
MATERNAL OUTCOME * PP PERSISTENCE 
hi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 100.000a 1 .000   
Continuity Correctionb 96.000 1 .000   
Likelihood Ratio 137.628 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 99.000 1 .000   
N of Valid Cases 100     
 
In  this  study  adverse maternal outcome is 100%  like preterm deliveries, antepartum 
hemorrhage ,persistent placenta previa, complete placenta previa, caesarean delivery 
and caesarean hysterectomy which have been shown in bar chart  as  well  with 
chisquare test since the p value is0.000. 
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Table VII A 
TERM * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
 
 
 
Term 
 
 
 
 
 
Preterm  
 
0 Count 48 15 63 
% within TERM 76.2% 23.8% 100.0% 
% within PP PERSISTENCE 87.3% 33.3% 63.0% 
% of Total 48.0% 15.0% 63.0% 
1 Count 7 30 37 
% within TERM 18.9% 81.1% 100.0% 
% within PP PERSISTENCE 12.7% 66.7% 37.0% 
% of Total 7.0% 30.0% 37.0% 
 Total Count 55 45 100 
% within TERM 55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Out of 100 antenatal placenta previa women,37 of them had preterm deliveries.out
of 37 cases ,30 patients (81%) had persistence of placenta previa.In persistent p
previa  patients,66.7% had preterm delivery. 
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Table VII B 
TERM * PP PERSISTENCE 
Chi-Square Tests 
 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 30.892a 1 .000   
Continuity Correctionb 28.621 1 .000   
Likelihood Ratio 32.576 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 30.583 1 .000   
N of Valid Cases 100     
 
 
The value of chi-squared test and the bar diagram shown that prematurity was  more 
common in persistent placenta previa. Thus the  prematurity was iatrogenic, which 
has been induced due to hemorrhage. 
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Table VIII A 
CAESAREAN HYSTERECTOMY * PP PERSISTENCE 
   PP PERSISTENCE  
   0 1 Total 
CAESAREAN 
HYSTERECTO
MY 
 
No 
 
 
 
Yes 
 
 
0 Count 55 27 82 
% within CAESAREAN
HYSTERECTOMY 
67.1% 32.9% 100.0% 
% within PP PERSISTENCE 100.0% 60.0% 82.0% 
% of Total 55.0% 27.0% 82.0% 
1 Count 0 18 18 
% within CAESAREAN
HYSTERECTOMY 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 40.0% 18.0% 
% of Total .0% 18.0% 18.0% 
 Total Count 55 45 100 
% within CAESAREAN
HYSTERECTOMY 
55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
In my study 18 cases underwent caesarean hysterectomy,all 18 cases had persistent 
placenta previa. 
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Table VIII B 
CAESAREAN HYSTERECTOMY * PP PERSISTENCE 
Chi-Square Tests 
 
Value Df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 26.829a 1 .000   
Continuity Correctionb 24.188 1 .000   
Likelihood Ratio 33.708 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 26.561 1 .000   
N of Valid Cases 100     
 
This bar diagram shows that there were 18 cases in whom caesarean hysterectomy 
done for placenta previa and its related complications. There is  100% correlation  in 
caesarean hysterectomy done in our hospital  and  placenta previa complications. 
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Table IX A 
HISTOPATHOLOGICAL EXAMINATION FINDINGS * PP 
PERSISTENCE 
   
PP PERSISTENCE  
   
0 1 Total 
HISTOPATHOLOG
ICAL 
EXAMINATION 
FINDINGS 
 
 
Placenta previa 
 
 
Placenta accreta 
 
 
Placenta increta  
 
 
Placenta percreta 
 
 
0 Count 55 27 82 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
67.1% 32.9% 100.0% 
% within PP PERSISTENCE 100.0% 60.0% 82.0% 
% of Total 55.0% 27.0% 82.0% 
1 Count 0 5 5 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 11.1% 5.0% 
% of Total .0% 5.0% 5.0% 
2 Count 0 6 6 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 13.3% 6.0% 
% of Total .0% 6.0% 6.0% 
3 Count 0 2 2 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 4.4% 2.0% 
% of Total .0% 2.0% 2.0% 
4 Count 0 5 5 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
.0% 100.0% 100.0% 
% within PP PERSISTENCE .0% 11.1% 5.0% 
% of Total .0% 5.0% 5.0% 
 Total Count 55 45 100 
% within HISTOPATHOLOGICAL 
EXAMINATION FINDINGS 
55.0% 45.0% 100.0% 
% within PP PERSISTENCE 100.0% 100.0% 100.0% 
% of Total 55.0% 45.0% 100.0% 
 
Out of 45 cases of persistent placenta previa,27 cases had underwent lower segment 
caesarean section and 18 cases had caesarean hysterectomy. 
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Table IX B 
HISTOPATHOLOGICAL EXAMINATION FINDINGS * PP 
PERSISTENCE 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 26.829a 4 .000 
Likelihood Ratio 33.708 4 .000 
Linear-by-Linear Association 20.618 1 .000 
N of Valid Cases 100   
 
Out  of 18 cases of hysterectomy in the histopathological  examination there are 5 
cases with placenta previa , 6 cases of placenta  accreta, 2 cases of placenta increta 
and 5 cases of placenta percreta. 
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TTable X A 
TERM * CESARIAN HYSTERECTOMY 
   CAESAREAN HYSTERECTOMY  
   0 1 Total 
 
 
 
Term 
 
 
 
 
Pre term 
 
 
 
0 Count 60 3 63 
% within TERM 95.2% 4.8% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
73.2% 16.7% 63.0% 
% of Total 60.0% 3.0% 63.0% 
1 Count 22 15 37 
% within TERM 59.5% 40.5% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
26.8% 83.3% 37.0% 
% of Total 22.0% 15.0% 37.0% 
 Total Count 82 18 100 
% within TERM 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 37 preterm cases,15 cases(40.5%) had persistent placenta previa   
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Table X B 
TERM * CESARIAN HYSTERECTOMY 
Chi-square test 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 20.216a 1 .000   
Continuity Correctionb 17.865 1 .000   
Likelihood Ratio 20.196 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 20.014 1 .000   
N of Valid Cases 100     
 
Out of 82 cases who underwent vaginal delivery 60(73%) were term and 22(27%) 
were preterm and 18 cases who underwent caesarean hysterectomy 3(17%) were term 
and 15(83%) were preterm. 
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Table XI A 
AGE GROUP * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   0 1 Total 
AGE GROUP 
 
<20 years  
 
 
 
 
21 -30 years  
 
 
 
 
>30 years 
1 Count 8 1 9 
% within AGE GROUP 88.9% 11.1% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
9.8% 5.6% 9.0% 
% of Total 8.0% 1.0% 9.0% 
2 Count 64 11 75 
% within AGE GROUP 85.3% 14.7% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
78.0% 61.1% 75.0% 
% of Total 64.0% 11.0% 75.0% 
3 Count 10 6 16 
% within AGE GROUP 62.5% 37.5% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
12.2% 33.3% 16.0% 
% of Total 10.0% 6.0% 16.0% 
 Total Count 82 18 100 
% within AGE GROUP 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 100 women 75 were between the age of 21 – 30 years, 9 were less than 20 
years and 16 were more than 30 years. 
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Table XI B 
AGE GROUP * CAESAREAN HYSTERECTOMY 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.976a 2 .083 
Likelihood Ratio 4.297 2 .117 
Linear-by-Linear Association 3.828 1 .050 
N of Valid Cases 100   
 
There is no statistical significance between the age distribution and PP complications 
as the p value is .08. 
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Table XII A 
PARITY * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   0 1 Total 
PARITY 
 
Primigravida 
 
 
 
 
Mulitigravida  
 
1 Count 34 1 35 
% within PARITY 97.1% 2.9% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
41.5% 5.6% 35.0% 
% of Total 34.0% 1.0% 35.0% 
2 Count 48 17 65 
% within PARITY 73.8% 26.2% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
58.5% 94.4% 65.0% 
% of Total 48.0% 17.0% 65.0% 
 Total Count 82 18 100 
% within PARITY 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 100 women 65 were multiparous women and in these 17 (26.2%) underwent 
caesarean hysterectomy. In the remaining 35 primigravida only one (2.9%) had 
caesarean hysterectomy. 
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Table XII B 
PARITY * CAESAREAN HYSTERECTOMY 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 8.365a 1 .004   
Continuity Correctionb 6.861 1 .009   
Likelihood Ratio 10.491 1 .001   
Fisher's Exact Test    .003 .002 
Linear-by-Linear Association 8.282 1 .004   
N of Valid Cases 100     
 
The chi-Square tests and the bar diagram shows that the multiparous women had 
increased chances of caesarean hysterectomy due to placenta previa complications. 
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Table XIII A 
PREVIOUS LSCS * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   
0 1 Total 
PREV.LSCS 0 Count 69 4 73 
% within PREV.LSCS 94.5% 5.5% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
84.1% 22.2% 73.0% 
% of Total 69.0% 4.0% 73.0% 
1 Count 12 8 20 
% within PREV.LSCS 60.0% 40.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
14.6% 44.4% 20.0% 
% of Total 12.0% 8.0% 20.0% 
2 Count 1 5 6 
% within PREV.LSCS 16.7% 83.3% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
1.2% 27.8% 6.0% 
% of Total 1.0% 5.0% 6.0% 
3 Count 0 1 1 
% within PREV.LSCS .0% 100.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
.0% 5.6% 1.0% 
% of Total .0% 1.0% 1.0% 
 Total Count 82 18 100 
% within PREV.LSCS 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 100 women 27 had previous caesarean delivery. In women with previous 
caesarean delivery 20 had 1prior caesarean delivery , 6 had 2prior caesarean 
deliveries  and 1 had prior 3 caesarean deliveries. In women with 1 previous 
caesarean delivery 8 (40%) underwent caesarean hysterectomy. In the group of 
women with 2 prior caesarean deliveries 5 (83.3%) underwent caesarean 
hysterectomy. The single woman with past h/o 3 caesarean deliveries also underwent 
caesarean hysterectomy. This shows the higher the number of previous caesarean 
deliveries the greater is the chance for woman to undergo caesarean hysterectomy. 
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Table XIII B 
PREVIOUS LSCS * CAESAREAN HYSTERECTOMY 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 36.218a 3 .000 
Likelihood Ratio 30.941 3 .000 
Linear-by-Linear Association 35.568 1 .000 
N of Valid Cases 100   
 
There is a statistically significant association between previous LSCS and caesarean 
hysterectomy for placenta previa complications  as the p valu--*e is .000 (which is 
<0.005) 
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Table XIV A 
PREVIOUS ABORTION * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   
0 1 Total 
PREV.ABOR 0 Count 62 8 70 
% within PREV.ABOR 88.6% 11.4% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
75.6% 44.4% 70.0% 
% of Total 62.0% 8.0% 70.0% 
1 Count 19 6 25 
% within PREV.ABOR 76.0% 24.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
23.2% 33.3% 25.0% 
% of Total 19.0% 6.0% 25.0% 
2 Count 0 3 3 
% within PREV.ABOR .0% 100.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
.0% 16.7% 3.0% 
% of Total .0% 3.0% 3.0% 
3 Count 1 1 2 
% within PREV.ABOR 50.0% 50.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
1.2% 5.6% 2.0% 
% of Total 1.0% 1.0% 2.0% 
 Total Count 82 18 100 
% within PREV.ABOR 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 100 women with placenta previa 30 cases had h/o previous abortion, out of 
which 25 women had h/o one abortion and in these, 6 women (25%) underwent 
caesarean hysterectomy. 3 women had h/o 2 abortions, 2 had h/o 3 recurrent 
abortions. 
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Table XIV B 
PREVIOUS ABORTION * CAESAREAN HYSTERECTOMY 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 17.712a 3 .001 
Likelihood Ratio 14.199 3 .003 
Linear-by-Linear Association 11.293 1 .001 
N of Valid Cases 100   
 
 
The association of previous abortion and PP complications is statistically significant 
as the p value is less than .001. 
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Table XV A 
PREVIOUS VAGINAL DELIVERY * CAESAREAN HYSTERECTOMY 
   CAESAREAN HYSTERECTOMY  
   0 1 Total 
PREV.V.D 0 Count 54 16 70 
% within PREV.V.D 77.1% 22.9% 100.0% 
% within CAES HYS 65.9% 88.9% 70.0% 
% of Total 54.0% 16.0% 70.0% 
1 Count 17 1 18 
% within PREV.V.D 94.4% 5.6% 100.0% 
% within CAES HYS 20.7% 5.6% 18.0% 
% of Total 17.0% 1.0% 18.0% 
2 Count 10 1 11 
% within PREV.V.D 90.9% 9.1% 100.0% 
% within CAES HYS 12.2% 5.6% 11.0% 
% of Total 10.0% 1.0% 11.0% 
3 Count 1 0 1 
% within PREV.V.D 100.0% .0% 100.0% 
% within CAES HYS 1.2% .0% 1.0% 
% of Total 1.0% .0% 1.0% 
 Total Count 82 18 100 
% within PREV.V.D 82.0% 18.0% 100.0% 
% within CAES HYS 100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 30 cases with previous vaginal delivery only 2 underwent caesarean 
hysterectomy due to placenta previa complications. 
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Table XV B 
PREVIOUS VAGINAL DELIVERY * CAESAREAN HYSTERECTOMY
Chi-Square Tests 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.818a 3 .282 
Likelihood Ratio 4.596 3 .204 
Linear-by-Linear Association 2.870 1 .090 
N of Valid Cases 100   
 
There is no statistical significance with placenta previa complications and previous 
vaginal delivery since the p value is .2 
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Table XVI A 
MATERNAL OUTCOME * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   0 1 Total 
MATERNAL OUTCOME 
 
Good 
 
 
 
 
 
Adverse 
1 Count 55 0 55 
% within MATERNAL 
OUTCOME 
100.0% .0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
67.1% .0% 55.0% 
% of Total 55.0% .0% 55.0% 
2 Count 27 18 45 
% within MATERNAL 
OUTCOME 
60.0% 40.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
32.9% 100.0% 45.0% 
% of Total 27.0% 18.0% 45.0% 
 Total Count 82 18 100 
% within MATERNAL 
OUTCOME 
82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 100 cases of placenta previa, 45 had persistent placenta previa at term, out of 
which 18 underwent caesarean hysterectomy for complications. All 45 cases were 
delivered by caesarean section which is indicative of adverse maternal outcome in 
persistent placenta previa. 
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Table XVI B 
MATERNAL OUTCOME * CAESAREAN HYSTERECTOMY 
Chi-Square Tests
 
Value Df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 26.829a 1 .000   
Continuity Correctionb 24.188 1 .000   
Likelihood Ratio 33.708 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 26.561 1 .000   
N of Valid Cases 100     
 
 
This bar chart shows Significant adverse maternal outcome with placenta previa 
persistence and its invasion. 
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Table XVII A 
TERM * CAESAREAN HYSTERECTOMY 
   CAESAREAN 
HYSTERECTOMY  
   0 1 Total 
 
 
Term  
 
 
 
 
Pre term  
0 Count 60 3 63 
% within TERM 95.2% 4.8% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
73.2% 16.7% 63.0% 
% of Total 60.0% 3.0% 63.0% 
1 Count 22 15 37 
% within TERM 59.5% 40.5% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
26.8% 83.3% 37.0% 
% of Total 22.0% 15.0% 37.0% 
 Total Count 82 18 100 
% within TERM 82.0% 18.0% 100.0% 
% within CAESAREAN
HYSTERECTOMY 
100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 37 preterm deliveries due to placenta previa, 15 cases underwent caesarean 
hysterectomy, which constitute 40.5%. Out of 18 cases of caesarean hysterectomy 15 
cases had preterm deliveries, which constitute 83.3%.  
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Table XVII B 
TERM * CAESAREAN HYSTERECTOMY 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 20.216a 1 .000   
Continuity Correctionb 17.865 1 .000   
Likelihood Ratio 20.196 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear Association 20.014 1 .000   
N of Valid Cases 100     
 
There is good statistical significance between preterm delivery and caesarean 
hysterectomy since p value is 0.000 
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Table XVIII A 
HISTOPATHOLOGICAL EXAMINATION FINDINGS * CAESAREAN 
HYSTERECTOMY 
   CAESAREAN HYSTERECTOMY  
   0 1 Total 
HISTOPATHOLOG
ICAL 
EXAMINATION 
FINDINGS 
 
Placenta previa 
 
 
Placenta accreta 
 
 
Placenta increta  
 
 
Placenta percreta 
0 Count 82 0 82 
% within HPE Findings 100.0% .0% 100.0% 
% within Ceas Hys  100.0% .0% 82.0% 
% of Total 82.0% .0% 82.0% 
1 Count 0 5 5 
% within HPE Findings .0% 100.0% 100.0% 
% within Ceas Hys .0% 27.8% 5.0% 
% of Total .0% 5.0% 5.0% 
2 Count 0 6 6 
% within HPE Findings .0% 100.0% 100.0% 
% within Ceas Hys .0% 33.3% 6.0% 
% of Total .0% 6.0% 6.0% 
3 Count 0 2 2 
% within HPE Findings .0% 100.0% 100.0% 
% within Ceas Hys .0% 11.1% 2.0% 
% of Total .0% 2.0% 2.0% 
4 Count 0 5 5 
% within HPE Findings .0% 100.0% 100.0% 
% within Ceas Hys .0% 27.8% 5.0% 
% of Total .0% 5.0% 5.0% 
 Total Count 82 18 100 
% within HPE Findings 82.0% 18.0% 100.0% 
% within Ceas Hys 100.0% 100.0% 100.0% 
% of Total 82.0% 18.0% 100.0% 
 
Out of 18 caesarean hysterectomy patients, 5 had only placenta previa, 6 had placenta 
accreta, 2 had placenta increta and 8 had placenta percreta, which is 27.8, 33.3, 11.1 
1nd 27.8% respectively. 
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Table XVIII B 
HISTOPATHOLOGICAL EXAMINATION FINDINGS * CAESAREAN 
HYSTERECTOMY 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 100.000a 4 .000 
Likelihood Ratio 94.279 4 .000 
Linear-by-Linear Association 76.850 1 .000 
N of Valid Cases 100   
 
The distribution of cases with placental invasion who underwent caesarean 
hysterectomy is shown in the bar diagram. 
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ROC curve for MOM value & persistent placenta previa 
 
 
The sensitivity and specificity of MSAFP with MOM value of >1.1 for persistence of 
placenta previa at term  are 75.6 and 85.5 respectively. 
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ROC curve for MOM value & persistent placenta previa 
ROC curve 
Variable MOM 
Classification variable PP_PERSISTENCE 
PP PERSISTENCE 
   
Sample size   100 
Positive group :  PP PERSISTENCE = 1 45 
Negative group :  PP PERSISTENCE = 0 55 
   
Disease prevalence (%) unknown 
   
Area under the ROC curve (AUC)  
   
Area under the ROC curve (AUC)  0.823636 
Standard Errora 0.0458 
95% Confidence intervalb 0.734623 to 0.892625 
z statistic 7.064 
Significance level P (Area=0.5) <0.0001 
 
Youden index 
   
Youden index J 0.6101 
Associated criterion >1.1 
   
 
Area under ROC curve is 0.82, which is to the left and above the tangential 
line and is statistically significant. Youden index, J is the distance between the 
summit of the curve and the tangential line and statistical significance is directly 
proportional to the length of the J line. In this study it is 0.61, which is statistically 
significant. The p value is <0.0001, shows statistical significance with MSAFP in 
MOM value taken at 16 – 20 weeks with persistence of placenta previa at term. 
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ROC curve for MOM value & persistent placenta previa 
Criterion values and coordinates of the ROC curve  
   
Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
≥0.1 100.00 92.1 - 100.0 0.00 0.0 - 6.5 1.00   
>0.1 100.00 92.1 - 100.0 1.82 0.05 - 9.7 1.02 0.00 
>0.2 95.56 84.9 - 99.5 7.27 2.0 - 17.6 1.03 0.61 
>0.56 95.56 84.9 - 99.5 30.91 19.1 - 44.8 1.38 0.14 
>0.6 93.33 81.7 - 98.6 40.00 27.0 - 54.1 1.56 0.17 
>0.64 93.33 81.7 - 98.6 41.82 28.7 - 55.9 1.60 0.16 
>0.7 91.11 78.8 - 97.5 47.27 33.7 - 61.2 1.73 0.19 
>0.75 91.11 78.8 - 97.5 50.91 37.1 - 64.6 1.86 0.17 
>0.8 86.67 73.2 - 94.9 56.36 42.3 - 69.7 1.99 0.24 
>0.98 86.67 73.2 - 94.9 70.91 57.1 - 82.4 2.98 0.19 
>1 84.44 70.5 - 93.5 70.91 57.1 - 82.4 2.90 0.22 
>1.01 84.44 70.5 - 93.5 72.73 59.0 - 83.9 3.10 0.21 
>1.04 82.22 67.9 - 92.0 72.73 59.0 - 83.9 3.01 0.24 
>1.05 80.00 65.4 - 90.4 74.55 61.0 - 85.3 3.14 0.27 
>1.09 80.00 65.4 - 90.4 80.00 67.0 - 89.6 4.00 0.25 
>1.1 75.56 60.5 - 87.1 85.45 73.3 - 93.5 5.19 0.29 
>1.27 68.89 53.4 - 81.8 85.45 73.3 - 93.5 4.74 0.36 
>1.3 68.89 53.4 - 81.8 89.09 77.8 - 95.9 6.31 0.35 
>1.37 66.67 51.0 - 80.0 89.09 77.8 - 95.9 6.11 0.37 
>1.4 60.00 44.3 - 74.3 90.91 80.0 - 97.0 6.60 0.44 
>1.72 51.11 35.8 - 66.3 90.91 80.0 - 97.0 5.62 0.54 
>1.8 48.89 33.7 - 64.2 92.73 82.4 - 98.0 6.72 0.55 
>2.3 6.67 1.4 - 18.3 92.73 82.4 - 98.0 0.92 1.01 
>2.4 6.67 1.4 - 18.3 94.55 84.9 - 98.9 1.22 0.99 
>2.5 4.44 0.5 - 15.1 98.18 90.3 - 100.0 2.44 0.97 
>2.6 2.22 0.06 - 11.8 98.18 90.3 - 100.0 1.22 1.00 
>2.7 2.22 0.06 - 11.8 100.00 93.5 - 100.0   0.98 
>2.9 0.00 0.0 - 7.9 100.00 93.5 - 100.0   1.00 
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ROC curve for MOM value  and Ceasarean  hysterectomy 
 
 The sensitivity of MSAFP in MOM values > 1.7 in persistent placenta previa 
patients for Caesarean hysterectomy due to placental invasion is 83.3% and specificity 
is 82.9%. 
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ROC curve for MOM value  and Ceasarean  hysterectomy 
ROC curve 
Variable MOM 
Classification variable CESA._HYS 
CAESAREAN HYSTERECTOMY 
   
Sample size   100 
Positive group :  CAESAREAN 
HYSTERECTOMY = 1 
18 
Negative group :  CAESAREAN 
HYSTERECTOMY = 0 
82 
   
Disease prevalence (%) unknown 
   
Area under the ROC curve (AUC)  
   
Area under the ROC curve (AUC)  0.811992 
Standard Errora 0.0589 
95% Confidence intervalb 0.721531 to 0.883183 
z statistic 5.293 
Significance level P (Area=0.5) <0.0001 
a DeLong et al., 1988 
b Binomial exact 
   
Youden index 
   
Youden index J 0.6626 
Associated criterion >1.7 
   
Area under ROC curve is 0.81, which is to the left and above the tangential line and 
is statistically significant. Youden index is the distance between the summit of the 
curve and the tangential line and statistical significance is directly proportional to the 
length of the J line. In this study it is 0.6, which is statistically significant. The p 
value is <0.0001. 
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ROC curve for MOM value  and Ceasarean  hysterectomy 
Criterion values and coordinates of the ROC curve  
  Criterion Sensitivity 95% CI Specificity 95% CI +LR -LR 
≥0.1 100.00 81.5 - 100.0 0.00 0.0 - 4.4 1.00   
>0.1 100.00 81.5 - 100.0 1.22 0.03 - 6.6 1.01 0.00 
>0.2 94.44 72.7 - 99.9 6.10 2.0 - 13.7 1.01 0.91 
>0.98 94.44 72.7 - 99.9 53.66 42.3 - 64.7 2.04 0.10 
>1 88.89 65.3 - 98.6 53.66 42.3 - 64.7 1.92 0.21 
>1.2 88.89 65.3 - 98.6 70.73 59.6 - 80.3 3.04 0.16 
>1.27 83.33 58.6 - 96.4 70.73 59.6 - 80.3 2.85 0.24 
>1.7 83.33 58.6 - 96.4 82.93 73.0 - 90.3 4.88 0.20 
>1.72 77.78 52.4 - 93.6 82.93 73.0 - 90.3 4.56 0.27 
>1.8 72.22 46.5 - 90.3 84.15 74.4 - 91.3 4.56 0.33 
>1.87 72.22 46.5 - 90.3 85.37 75.8 - 92.2 4.94 0.33 
>1.9 55.56 30.8 - 78.5 85.37 75.8 - 92.2 3.80 0.52 
>2 44.44 21.5 - 69.2 87.80 78.7 - 94.0 3.64 0.63 
>2.01 44.44 21.5 - 69.2 89.02 80.2 - 94.9 4.05 0.62 
>2.1 27.78 9.7 - 53.5 89.02 80.2 - 94.9 2.53 0.81 
>2.2 16.67 3.6 - 41.4 91.46 83.2 - 96.5 1.95 0.91 
>2.28 11.11 1.4 - 34.7 91.46 83.2 - 96.5 1.30 0.97 
>2.5 11.11 1.4 - 34.7 98.78 93.4 - 100.0 9.11 0.90 
>2.6 5.56 0.1 - 27.3 98.78 93.4 - 100.0 4.56 0.96 
>2.7 5.56 0.1 - 27.3 100.00 95.6 - 100.0   0.94 
>2.9 0.00 0.0 - 18.5 100.00 95.6 - 100.0   1.00 
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Table XIX 
T-Test 
 CAESAREAN 
HYSTERECTOMY N Mean Std. Deviation Std. Error Mean 
MSAFP 1 18 191.78 57.283 13.502 
0 82 113.02 65.003 7.178 
MOM 1 18 1.898 .5985 .1411 
0 82 1.058 .6523 .0720 
 
MSAFP value for 18 cases who underwent caesarean hysterectomy is 191.78 and 82 
cases who didn’t undergo hysterectomy the MSAFP value is 113.02 and MOM values 
for the same is 1.898 and 1.058 respectively. It shows that the women who underwent 
caesarean hysterectomy had higher values of MSAFP. 
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Table XX 
Multiple Logistics Regression 
Variables in the Equation 
   Score df Sig. 
Step 0 Variables PARITY(1) 8.365 1 .004 
MOM 20.408 1 .000 
PREV.LSCS 35.927 1 .000 
MATERNALOUTCOME(1) 26.829 1 .000 
TERM 20.216 1 .000 
PREV.ABOR 11.408 1 .001 
 Overall Statistics 47.803 6 .000 
 
The variables like multiparity, MOM value, Prev., LSCS, Adverse Maternal outcome, 
preterm delivery and h/o pre., abortion have significant p value between 0.001 to 
0.004. So these variables are considered risk factors for placenta previa persistence 
and intra caesarean hysterectomy. 
With multiple logistic regression this table shows that the various characteristics of 
the patients like multiparity, MOM value of more than 1.9, previous caesarean 
delivery and previous abortions are considered as independent risk factors.With this it 
shows that adverse maternal outcomes like maternal hemorrhage and preterm delivery 
are directly related with these risk factors .Since all variables have Pvalue  less than 
0.005 
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                                                  DISCUSSION 
 100 Antenatal women had sonographic evidence of placenta previa at 
15-20 weeks of gestation  were subjected for maternal serum alpha 
fetoprotein screening. 
 All 100 women were delivered either vaginally or by caesarean 
section of non anomalous live born infants at or after 24 weeks of gestation. 
Out of 100 patients, 45 (45%) had persistent  placenta previa confirmed at 
the time of delivery. 
 Of these 45 women who had placenta previa at the time of delivery, 
18 cases (40%) underwent caesarean hysterectomy .  out of these 18 cases 
of caesarean hysterectomy, 13 cases(72%) had abnormal placental invasion,  
which was confirmed by histopathological study .Out of these 13 cases, 6 
cases were placenta accreta,2 cases  were increta and 5 cases were  placenta 
percreta. In these 18 cases most of them had preterm delivery.  
 In this study  27 cases had previous caesarean delivery . , out of 27, 
26 cases  had persistence of placenta  previa at term compared to 19 out of 
54 cases with  non prior caesarean delivery. So Women who had prior 
caesarean delivery had a higher incidence of persistence of placenta previa 
in this study There  was good  statistical significance  with parity, previous 
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lscs, previous vaginal delivery but  there was no statistical significance   
with maternal age, previous abortion regarding  persistence of placenta 
previa. 
 The likelihood of persistence increased significantly with increasing 
MSAFP in MOM value .The mean MSAFP in MOM value for persistent 
placenta previa was >1.1 and the mean MSAFP in MOM value for 
caesarean hysterectomy was  >1.7. 
 Mid trimester MSAFP  <1.1 MOM  was associated  with decreased 
incidence of persistence of placenta previa. The 1.1 MOM cut off was then 
applied  to subgroups of women with  incomplete and complete previa and 
found that women with incomplete placenta previa who have  <1.1MOM 
are  not presented with persistence of placenta previa at term .Thus  when 
MSAFP >1.1 MOM there is significant statistical correlation of persistence 
of placenta previa since p value is0.0001 (95% CI 60-87%). 
 Using multiple logistic regression ,traditional risk factors for placenta 
previa persistence were compared with MSAFP MOM value. Thus MSAFP 
is considered as an independent risk factor and can be used as predictor for 
detecting persistence of placenta previa at term, in the second trimester 
itself.     
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                                            CONCLUSION 
 Antenatal women with sonographic evidence of placenta previa 
between 15-20 weeks of gestation have a greater likelihood of 
persistent placenta previa with increased values of MSAFP. 
 If   MSAFP values <1.1 MOM there is a decreased likelihood of 
persistence of placenta previa at term.  
 MSAFP   proved to be particularly useful in subgroup of women 
having incomplete placenta previa at 15-20 weeks of gestation.  
 MSAFP value more than 1.1 MOM is significantly associated with  
the risk of persistence of previa comparable to other risk factors such 
as complete placenta previa, multi parity and previous caesarean 
delivery. 
 In this study the risk   factor associated with highest risk of 
placenta previa  persistence is prior caesarean delivery.  
 Also found that there is a great association between MSAFP and 
occurrence of placenta accreta, thus deficient decidualization is likely 
responsible for elevated MSAFP due to disruption of placental barrier. 
In the present scenario, clinicians and patients are interested in 
having a suitable serum marker which represents a persistence of placenta 
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previa at term in early pregnancy. Thus this data confirms the above 
mentioned statement. 
 In this study  if the value of MSAFP is >1.1MOM  then there is 
high chance of occurrence of persistent  placenta previa and if the 
values are >1.7MOM  there is higher chance of occurrence of adherent 
placenta. 
 This study reveals elevated MSAFP is an adjuvant tool to diagnose 
the persistence of placenta previa in addition with Sonography. So if 
MSAFP level >1.7 MOM and Sonography reveals the placental 
invasion, patient can be counselled for increase risk of caesarean 
hysterectomy.                                                    
 It helps the clinician to motivate the patient to have tertiary level of 
care and plan for elective surgery. 
 The combination of   Ultrasound  and MSAFP is cost effective  
compared with MRI in diagnosing persistent placenta previa and its  
invasion. 
 Thus the estimation of maternal serum alpha fetoprotein in 16-20 
weeks of gestation in these patients can predict the persistence and 
invasion of placenta previa at term. 

